CN112608892A - Method for serum-free separation and subculture of umbilical cord mesenchymal stem cells by using platelet lysate - Google Patents
Method for serum-free separation and subculture of umbilical cord mesenchymal stem cells by using platelet lysate Download PDFInfo
- Publication number
- CN112608892A CN112608892A CN202011567586.1A CN202011567586A CN112608892A CN 112608892 A CN112608892 A CN 112608892A CN 202011567586 A CN202011567586 A CN 202011567586A CN 112608892 A CN112608892 A CN 112608892A
- Authority
- CN
- China
- Prior art keywords
- mesenchymal stem
- stem cells
- cells
- bottle
- umbilical cord
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000002901 mesenchymal stem cell Anatomy 0.000 title claims abstract description 322
- 210000003954 umbilical cord Anatomy 0.000 title claims abstract description 276
- 238000000034 method Methods 0.000 title claims abstract description 124
- 239000006166 lysate Substances 0.000 title claims abstract description 27
- 238000000926 separation method Methods 0.000 title abstract description 5
- 210000004027 cell Anatomy 0.000 claims abstract description 289
- 239000001963 growth medium Substances 0.000 claims abstract description 237
- 239000000243 solution Substances 0.000 claims abstract description 92
- 230000001502 supplementing effect Effects 0.000 claims abstract description 73
- 108010019160 Pancreatin Proteins 0.000 claims abstract description 50
- 229940055695 pancreatin Drugs 0.000 claims abstract description 50
- 230000007910 cell fusion Effects 0.000 claims abstract description 46
- 238000004140 cleaning Methods 0.000 claims abstract description 43
- 230000000694 effects Effects 0.000 claims abstract description 24
- 239000007788 liquid Substances 0.000 claims abstract description 24
- 238000010790 dilution Methods 0.000 claims abstract description 18
- 239000012895 dilution Substances 0.000 claims abstract description 18
- 239000012879 subculture medium Substances 0.000 claims abstract description 18
- 239000006285 cell suspension Substances 0.000 claims abstract description 13
- 239000002244 precipitate Substances 0.000 claims abstract description 8
- 210000001519 tissue Anatomy 0.000 claims description 196
- 239000002609 medium Substances 0.000 claims description 97
- 239000012981 Hank's balanced salt solution Substances 0.000 claims description 77
- 238000012258 culturing Methods 0.000 claims description 64
- 239000013589 supplement Substances 0.000 claims description 63
- 235000015110 jellies Nutrition 0.000 claims description 62
- 239000008274 jelly Substances 0.000 claims description 62
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 44
- 238000005303 weighing Methods 0.000 claims description 42
- 238000005520 cutting process Methods 0.000 claims description 37
- PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 claims description 35
- 229940035024 thioglycerol Drugs 0.000 claims description 35
- 229930091371 Fructose Natural products 0.000 claims description 32
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 32
- 239000005715 Fructose Substances 0.000 claims description 32
- 238000002156 mixing Methods 0.000 claims description 32
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 31
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 30
- 239000000463 material Substances 0.000 claims description 30
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 28
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims description 23
- 108091006905 Human Serum Albumin Proteins 0.000 claims description 22
- 102000008100 Human Serum Albumin Human genes 0.000 claims description 22
- 102000004877 Insulin Human genes 0.000 claims description 22
- 108090001061 Insulin Proteins 0.000 claims description 22
- 229940125396 insulin Drugs 0.000 claims description 22
- 208000007536 Thrombosis Diseases 0.000 claims description 18
- 210000001367 artery Anatomy 0.000 claims description 18
- 210000002615 epidermis Anatomy 0.000 claims description 18
- 210000003462 vein Anatomy 0.000 claims description 18
- 102100022464 5'-nucleotidase Human genes 0.000 claims description 16
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 16
- 101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 claims description 16
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 16
- 102100037241 Endoglin Human genes 0.000 claims description 15
- 101000881679 Homo sapiens Endoglin Proteins 0.000 claims description 15
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 claims description 15
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims description 15
- 101000800116 Homo sapiens Thy-1 membrane glycoprotein Proteins 0.000 claims description 15
- 102100022338 Integrin alpha-M Human genes 0.000 claims description 15
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 claims description 15
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims description 15
- 102100033523 Thy-1 membrane glycoprotein Human genes 0.000 claims description 15
- 238000001914 filtration Methods 0.000 claims description 15
- 239000001103 potassium chloride Substances 0.000 claims description 15
- 235000011164 potassium chloride Nutrition 0.000 claims description 15
- 239000011780 sodium chloride Substances 0.000 claims description 15
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 14
- -1 CD31 Proteins 0.000 claims description 14
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 14
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 14
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 14
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 14
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 14
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 14
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims description 14
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 14
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 14
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 claims description 14
- 229960001230 asparagine Drugs 0.000 claims description 14
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 claims description 14
- 239000012982 microporous membrane Substances 0.000 claims description 14
- 238000002360 preparation method Methods 0.000 claims description 14
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 claims description 14
- 230000001954 sterilising effect Effects 0.000 claims description 14
- 238000004659 sterilization and disinfection Methods 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 238000007865 diluting Methods 0.000 claims description 12
- 238000005259 measurement Methods 0.000 claims description 12
- 230000001376 precipitating effect Effects 0.000 claims description 12
- 238000005070 sampling Methods 0.000 claims description 12
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims description 11
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims description 11
- 239000011159 matrix material Substances 0.000 claims description 11
- 238000001514 detection method Methods 0.000 claims description 10
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 9
- 239000012679 serum free medium Substances 0.000 claims description 8
- IOCJWNPYGRVHLN-MMALYQPHSA-N (2r)-2-amino-3-[[(2r)-2-amino-2-carboxyethyl]disulfanyl]propanoic acid;hydrochloride Chemical compound Cl.OC(=O)[C@@H](N)CSSC[C@H](N)C(O)=O IOCJWNPYGRVHLN-MMALYQPHSA-N 0.000 claims description 7
- QZNNVYOVQUKYSC-JEDNCBNOSA-N (2s)-2-amino-3-(1h-imidazol-5-yl)propanoic acid;hydron;chloride Chemical compound Cl.OC(=O)[C@@H](N)CC1=CN=CN1 QZNNVYOVQUKYSC-JEDNCBNOSA-N 0.000 claims description 7
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 claims description 7
- PWKSKIMOESPYIA-UHFFFAOYSA-N 2-acetamido-3-sulfanylpropanoic acid Chemical compound CC(=O)NC(CS)C(O)=O PWKSKIMOESPYIA-UHFFFAOYSA-N 0.000 claims description 7
- QDGAVODICPCDMU-UHFFFAOYSA-N 2-amino-3-[3-[bis(2-chloroethyl)amino]phenyl]propanoic acid Chemical compound OC(=O)C(N)CC1=CC=CC(N(CCCl)CCCl)=C1 QDGAVODICPCDMU-UHFFFAOYSA-N 0.000 claims description 7
- KWTQSFXGGICVPE-UHFFFAOYSA-N 2-amino-5-(diaminomethylideneamino)pentanoic acid;hydron;chloride Chemical compound Cl.OC(=O)C(N)CCCN=C(N)N KWTQSFXGGICVPE-UHFFFAOYSA-N 0.000 claims description 7
- 239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 claims description 7
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 claims description 7
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 7
- 235000019743 Choline chloride Nutrition 0.000 claims description 7
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims description 7
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 claims description 7
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 claims description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 7
- 239000004471 Glycine Substances 0.000 claims description 7
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 claims description 7
- 239000007836 KH2PO4 Substances 0.000 claims description 7
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 claims description 7
- CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 claims description 7
- FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 claims description 7
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 7
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 7
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 7
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 7
- 229930182816 L-glutamine Natural products 0.000 claims description 7
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 7
- 229930182844 L-isoleucine Natural products 0.000 claims description 7
- 239000004395 L-leucine Substances 0.000 claims description 7
- 235000019454 L-leucine Nutrition 0.000 claims description 7
- BVHLGVCQOALMSV-JEDNCBNOSA-N L-lysine hydrochloride Chemical compound Cl.NCCCC[C@H](N)C(O)=O BVHLGVCQOALMSV-JEDNCBNOSA-N 0.000 claims description 7
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 7
- 229930195722 L-methionine Natural products 0.000 claims description 7
- 229930182821 L-proline Natural products 0.000 claims description 7
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 7
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 claims description 7
- 239000004473 Threonine Substances 0.000 claims description 7
- 229930003779 Vitamin B12 Natural products 0.000 claims description 7
- 229930003756 Vitamin B7 Natural products 0.000 claims description 7
- INAPMGSXUVUWAF-GCVPSNMTSA-N [(2r,3s,5r,6r)-2,3,4,5,6-pentahydroxycyclohexyl] dihydrogen phosphate Chemical compound OC1[C@H](O)[C@@H](O)C(OP(O)(O)=O)[C@H](O)[C@@H]1O INAPMGSXUVUWAF-GCVPSNMTSA-N 0.000 claims description 7
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 claims description 7
- 229960003767 alanine Drugs 0.000 claims description 7
- 229960005261 aspartic acid Drugs 0.000 claims description 7
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 claims description 7
- XXWCODXIQWIHQN-UHFFFAOYSA-N butane-1,4-diamine;hydron;dichloride Chemical compound Cl.Cl.NCCCCN XXWCODXIQWIHQN-UHFFFAOYSA-N 0.000 claims description 7
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 claims description 7
- 229960003178 choline chloride Drugs 0.000 claims description 7
- SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 claims description 7
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 claims description 7
- JZCCFEFSEZPSOG-UHFFFAOYSA-L copper(II) sulfate pentahydrate Chemical compound O.O.O.O.O.[Cu+2].[O-]S([O-])(=O)=O JZCCFEFSEZPSOG-UHFFFAOYSA-L 0.000 claims description 7
- 229960002989 glutamic acid Drugs 0.000 claims description 7
- SURQXAFEQWPFPV-UHFFFAOYSA-L iron(2+) sulfate heptahydrate Chemical compound O.O.O.O.O.O.O.[Fe+2].[O-]S([O-])(=O)=O SURQXAFEQWPFPV-UHFFFAOYSA-L 0.000 claims description 7
- SZQUEWJRBJDHSM-UHFFFAOYSA-N iron(3+);trinitrate;nonahydrate Chemical compound O.O.O.O.O.O.O.O.O.[Fe+3].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O SZQUEWJRBJDHSM-UHFFFAOYSA-N 0.000 claims description 7
- 229960000310 isoleucine Drugs 0.000 claims description 7
- 229960003136 leucine Drugs 0.000 claims description 7
- AGBQKNBQESQNJD-UHFFFAOYSA-M lipoate Chemical compound [O-]C(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-M 0.000 claims description 7
- 235000019136 lipoic acid Nutrition 0.000 claims description 7
- 229910001629 magnesium chloride Inorganic materials 0.000 claims description 7
- 229960004452 methionine Drugs 0.000 claims description 7
- 229910000402 monopotassium phosphate Inorganic materials 0.000 claims description 7
- 235000019796 monopotassium phosphate Nutrition 0.000 claims description 7
- 229910000403 monosodium phosphate Inorganic materials 0.000 claims description 7
- 235000019799 monosodium phosphate Nutrition 0.000 claims description 7
- 229960003531 phenolsulfonphthalein Drugs 0.000 claims description 7
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 claims description 7
- 229960002429 proline Drugs 0.000 claims description 7
- FCHXJFJNDJXENQ-UHFFFAOYSA-N pyridoxal hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(C=O)=C1O FCHXJFJNDJXENQ-UHFFFAOYSA-N 0.000 claims description 7
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims description 7
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 claims description 7
- 229960004172 pyridoxine hydrochloride Drugs 0.000 claims description 7
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 claims description 7
- 239000011764 pyridoxine hydrochloride Substances 0.000 claims description 7
- 229960002477 riboflavin Drugs 0.000 claims description 7
- 235000019192 riboflavin Nutrition 0.000 claims description 7
- 239000002151 riboflavin Substances 0.000 claims description 7
- 229960001153 serine Drugs 0.000 claims description 7
- IFGCUJZIWBUILZ-UHFFFAOYSA-N sodium 2-[[2-[[hydroxy-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyphosphoryl]amino]-4-methylpentanoyl]amino]-3-(1H-indol-3-yl)propanoic acid Chemical compound [Na+].C=1NC2=CC=CC=C2C=1CC(C(O)=O)NC(=O)C(CC(C)C)NP(O)(=O)OC1OC(C)C(O)C(O)C1O IFGCUJZIWBUILZ-UHFFFAOYSA-N 0.000 claims description 7
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 7
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 7
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 claims description 7
- 229940054269 sodium pyruvate Drugs 0.000 claims description 7
- 229960000344 thiamine hydrochloride Drugs 0.000 claims description 7
- 235000019190 thiamine hydrochloride Nutrition 0.000 claims description 7
- 239000011747 thiamine hydrochloride Substances 0.000 claims description 7
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 claims description 7
- 229960002663 thioctic acid Drugs 0.000 claims description 7
- 229960002898 threonine Drugs 0.000 claims description 7
- 229940104230 thymidine Drugs 0.000 claims description 7
- 229960004441 tyrosine Drugs 0.000 claims description 7
- 229960004295 valine Drugs 0.000 claims description 7
- 235000019163 vitamin B12 Nutrition 0.000 claims description 7
- 239000011715 vitamin B12 Substances 0.000 claims description 7
- 235000011912 vitamin B7 Nutrition 0.000 claims description 7
- 239000011735 vitamin B7 Substances 0.000 claims description 7
- RZLVQBNCHSJZPX-UHFFFAOYSA-L zinc sulfate heptahydrate Chemical compound O.O.O.O.O.O.O.[Zn+2].[O-]S([O-])(=O)=O RZLVQBNCHSJZPX-UHFFFAOYSA-L 0.000 claims description 7
- 238000005119 centrifugation Methods 0.000 claims description 3
- 230000007480 spreading Effects 0.000 claims description 2
- 238000003892 spreading Methods 0.000 claims description 2
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 claims 6
- 230000001413 cellular effect Effects 0.000 claims 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 150
- 229910002092 carbon dioxide Inorganic materials 0.000 description 83
- 238000002955 isolation Methods 0.000 description 31
- 229920006395 saturated elastomer Polymers 0.000 description 28
- 230000003833 cell viability Effects 0.000 description 27
- 210000000130 stem cell Anatomy 0.000 description 25
- 229910002091 carbon monoxide Inorganic materials 0.000 description 24
- 239000013049 sediment Substances 0.000 description 24
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 17
- 101800003838 Epidermal growth factor Proteins 0.000 description 17
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 17
- 229940116977 epidermal growth factor Drugs 0.000 description 17
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 17
- 241000282414 Homo sapiens Species 0.000 description 16
- 241001337904 Gordonia <angiosperm> Species 0.000 description 15
- 230000004069 differentiation Effects 0.000 description 14
- 238000011081 inoculation Methods 0.000 description 14
- 239000000203 mixture Substances 0.000 description 14
- 239000002054 inoculum Substances 0.000 description 13
- AZUYLZMQTIKGSC-UHFFFAOYSA-N 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one Chemical compound ClC=1C(=C2C=NNC2=CC=1C)C=1C(=NN(C=1C)C1CC2(CN(C2)C(C=C)=O)C1)C=1C=C2C=NN(C2=CC=1)C AZUYLZMQTIKGSC-UHFFFAOYSA-N 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 238000011072 cell harvest Methods 0.000 description 11
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 8
- 239000012091 fetal bovine serum Substances 0.000 description 8
- 238000009472 formulation Methods 0.000 description 7
- 230000008569 process Effects 0.000 description 6
- 230000035899 viability Effects 0.000 description 6
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 5
- 238000012136 culture method Methods 0.000 description 5
- 230000003394 haemopoietic effect Effects 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- 238000002054 transplantation Methods 0.000 description 5
- 230000001464 adherent effect Effects 0.000 description 4
- 230000002293 adipogenic effect Effects 0.000 description 4
- 210000001185 bone marrow Anatomy 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 230000002188 osteogenic effect Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000004017 serum-free culture medium Substances 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 210000000845 cartilage Anatomy 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000003292 glue Substances 0.000 description 3
- 208000024908 graft versus host disease Diseases 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- PZASAAIJIFDWSB-CKPDSHCKSA-N 8-[(1S)-1-[8-(trifluoromethyl)-7-[4-(trifluoromethyl)cyclohexyl]oxynaphthalen-2-yl]ethyl]-8-azabicyclo[3.2.1]octane-3-carboxylic acid Chemical compound FC(F)(F)C=1C2=CC([C@@H](N3C4CCC3CC(C4)C(O)=O)C)=CC=C2C=CC=1OC1CCC(C(F)(F)F)CC1 PZASAAIJIFDWSB-CKPDSHCKSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
- 102100037362 Fibronectin Human genes 0.000 description 2
- 108010067306 Fibronectins Proteins 0.000 description 2
- 208000009329 Graft vs Host Disease Diseases 0.000 description 2
- 102000004058 Leukemia inhibitory factor Human genes 0.000 description 2
- 108090000581 Leukemia inhibitory factor Proteins 0.000 description 2
- 238000004115 adherent culture Methods 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- YRQNKMKHABXEJZ-UVQQGXFZSA-N chembl176323 Chemical compound C1C[C@]2(C)[C@@]3(C)CC(N=C4C[C@]5(C)CCC6[C@]7(C)CC[C@@H]([C@]7(CC[C@]6(C)[C@@]5(C)CC4=N4)C)CCCCCCCC)=C4C[C@]3(C)CCC2[C@]2(C)CC[C@H](CCCCCCCC)[C@]21C YRQNKMKHABXEJZ-UVQQGXFZSA-N 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000009816 chondrogenic differentiation Effects 0.000 description 2
- 230000002648 chondrogenic effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 229940126864 fibroblast growth factor Drugs 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 238000011134 hematopoietic stem cell transplantation Methods 0.000 description 2
- 230000007365 immunoregulation Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000003716 mesoderm Anatomy 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- 239000008055 phosphate buffer solution Substances 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000010008 shearing Methods 0.000 description 2
- 238000007447 staining method Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 102100032528 C-type lectin domain family 11 member A Human genes 0.000 description 1
- 101710167766 C-type lectin domain family 11 member A Proteins 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- XKMLYUALXHKNFT-UUOKFMHZSA-N Guanosine-5'-triphosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XKMLYUALXHKNFT-UUOKFMHZSA-N 0.000 description 1
- 101500025419 Homo sapiens Epidermal growth factor Proteins 0.000 description 1
- 101000851181 Homo sapiens Epidermal growth factor receptor Proteins 0.000 description 1
- 101000976075 Homo sapiens Insulin Proteins 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000029578 Muscle disease Diseases 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 241000906034 Orthops Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- 208000009527 Refractory anemia Diseases 0.000 description 1
- 206010072684 Refractory cytopenia with unilineage dysplasia Diseases 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 230000009815 adipogenic differentiation Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000011759 adipose tissue development Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 230000022159 cartilage development Effects 0.000 description 1
- 230000032677 cell aging Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 102000058223 human VEGFA Human genes 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 229940116978 human epidermal growth factor Drugs 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000003832 immune regulation Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000013394 immunophenotyping Methods 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- GVUGOAYIVIDWIO-UFWWTJHBSA-N nepidermin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C(C)C)C(C)C)C1=CC=C(O)C=C1 GVUGOAYIVIDWIO-UFWWTJHBSA-N 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 230000009818 osteogenic differentiation Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 210000001778 pluripotent stem cell Anatomy 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 239000003761 preservation solution Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 208000037922 refractory disease Diseases 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 210000001032 spinal nerve Anatomy 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 210000001644 umbilical artery Anatomy 0.000 description 1
- 210000003606 umbilical vein Anatomy 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0665—Blood-borne mesenchymal stem cells, e.g. from umbilical cord blood
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C12N2500/12—Light metals, i.e. alkali, alkaline earth, Be, Al, Mg
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C12N2500/12—Light metals, i.e. alkali, alkaline earth, Be, Al, Mg
- C12N2500/14—Calcium; Ca chelators; Calcitonin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C12N2500/12—Light metals, i.e. alkali, alkaline earth, Be, Al, Mg
- C12N2500/16—Magnesium; Mg chelators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C12N2500/20—Transition metals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C12N2500/20—Transition metals
- C12N2500/24—Iron; Fe chelators; Transferrin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/32—Amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/34—Sugars
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/35—Polyols, e.g. glycerin, inositol
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/36—Lipids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/38—Vitamins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/40—Nucleotides, nucleosides or bases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/70—Undefined extracts
- C12N2500/80—Undefined extracts from animals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/11—Epidermal growth factor [EGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/30—Hormones
- C12N2501/33—Insulin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/998—Proteins not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
- C12N2509/10—Mechanical dissociation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Developmental Biology & Embryology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Rheumatology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The invention relates to a method for serum-free separation and subculture of umbilical cord mesenchymal stem cells by using a platelet lysate. In one aspect, the invention relates to a method for subculturing umbilical cord mesenchymal stem cells, comprising the following steps: inoculating primary P0-generation mesenchymal stem cells into a culture bottle, supplementing a passage complete culture medium, placing the culture bottle in a CO2 incubator for culture until the cell fusion degree reaches 70-80%, discarding the old culture medium, cleaning the cells with D-hanks liquid, adding a recombinant pancreatin solution for digesting the cells to make the cells fall off, adding the D-hanks liquid for dilution, combining all cell suspensions into a centrifugal tube, centrifuging, and resuspending the cell precipitates with the passage complete culture medium to obtain the P1-generation mesenchymal stem cells; the umbilical cord mesenchymal stem cells of the subsequent generations, for example, to the P10 generation, are obtained by continuing the subculture method from the P0 generation to the P1 generation as such. Also relates to a complete subculture medium for subculturing umbilical cord mesenchymal stem cells. The method of the invention and the culture medium used exhibit excellent technical effects as described in the specification.
Description
Technical Field
The invention belongs to the technical field of biology, and relates to a method for separating and passaging umbilical cord mesenchymal stem cells from an umbilical cord. The invention also relates to a culture medium and a related test solution used in the umbilical cord mesenchymal stem cell culture, and also relates to application of a serum-free culture medium in separation and passage of umbilical cord mesenchymal stem cells. When the umbilical cord mesenchymal stem cells are isolated, cultured and subcultured by using the method, the excellent technical effect can be presented. In particular, the invention relates to methods for isolating and subculturing mesenchymal stem cells from umbilical cord using serum-free medium. In particular, platelet lysate is included in the serum-free medium used in the isolated culture and subculture of the umbilical cord mesenchymal stem cells according to the present invention.
Background
Mesenchymal Stem Cells (MSCs), such as human mesenchymal stem cells, were first isolated from bone marrow and a class of tissue stem cells derived from the mesoderm, which have the potential for multipotent differentiation and the ability to self-renew, have the ability to differentiate into various adult cells, such as osteoblasts, chondrocytes, adipocytes, endothelial cells, nerve cells, muscle cells, hepatocytes, etc., under specific conditions in vivo and in vitro (Cap AI. mesenchymal stem cells. J Orthop Res.1991,9:641-650.Pittenger MF, Mackay AM, Beck, et al. multilineage patent of epithelial man stem cells. science.1999; 284:143 Across 147). Recent research shows that the mesenchymal stem cells have the functions of immunoregulation and hematopoietic support, and are easy to introduce and express exogenous genes. Therefore, the mesenchymal stem cells are not only seed cells in the construction of tissue engineering bone, cartilage and cardiac muscle and important carrier cells in gene therapy, but also have wide application prospect in hematopoietic stem cell transplantation and organ transplantation because the mesenchymal stem cells promote hematopoietic reconstruction and inhibit graft-versus-host reaction. Mesenchymal stem cells have the characteristic of adherent growth in vitro, and by utilizing the characteristic, the mesenchymal stem cells are successfully separated and cultured from various tissues such as liver, kidney, pancreas, muscle, cartilage, skin, peripheral blood and the like.
Stem cells are progenitors of human cells, and all cells in our body are derived from stem cells. When cells in the body age, die or the lesion denatures, stem cells grow and transform out of cells that can replace them. As seed cells, the compound is mainly used for treating various refractory diseases of tissue cells and organ injuries which cannot be naturally repaired by an organism clinically; as immunoregulatory cells, for the treatment of immune rejection and autoimmune diseases. Human mesenchymal stem cells are important members of a stem cell family, are derived from mesoderm in early development and belong to pluripotent stem cells, and are discovered in bone marrow initially, so that the human mesenchymal stem cells are increasingly concerned because of the characteristics of multidirectional differentiation potential, hematopoietic support, stem cell implantation promotion, immune regulation, self-replication and the like. Initial clinical studies were conducted in 1995 by Lazarus et al, who collected autologous MSCs of patients with hematological tumors in remission, cultured for 4-7 weeks in vitro for expansion, and then injected intravenously into patients, who were divided into 3 groups, administered different doses of MSCs, respectively, and no toxic side effects were observed after injection, suggesting that MSCs are safe and reliable for transplantation therapy. Then, clinical reports of autologous MSC are gradually increased, and the disease types comprise hematopoietic reconstruction after radiotherapy and chemotherapy, graft-versus-host disease (GVHD), heart system diseases and the like, and clinical intravenous infusion is proved to be safe and reliable in the reports.
The isolation culture and subculture process of mesenchymal stem cells are key steps related to the use safety of stem cells as therapeutic drugs. The composition of the culture process, in particular of the culture medium, is a major influencing parameter. In the methods described in the prior documents, when mesenchymal stem cells are isolated and subcultured, the culture medium to be used is usually supplemented with serum, such as fetal bovine serum, particularly 10% fetal bovine serum, and for example, the mesenchymal stem cells are isolated and subcultured usually in MSC complete medium (which is DMEM-F12 medium containing 10% fetal bovine serum).
On the one hand, however, the cost of fetal bovine serum is rather high, which is disadvantageous for the culture of mesenchymal stem cells; on the other hand, the presence of fetal bovine serum as an exogenous material of animal origin in stem cells poses a potential risk to the safety of clinical use of the cells. Therefore, serum-free isolation and subculture of mesenchymal stem cells are of interest.
Umbilical Cord Mesenchymal Stem Cells (UCMSCs) are multifunctional Stem Cells existing in Umbilical cord tissues of newborn, can be differentiated into a plurality of tissue Cells, and have wide clinical application prospects. The application of the inactivated umbilical cord serum culture system can successfully amplify human umbilical cord mesenchymal stem cells, the cultured cells have the basic characteristics of the mesenchymal stem cells, and theoretical basis is provided for establishing a mesenchymal stem cell bank and clinical application, however, the yield of the method is quite limited. Umbilical cord Mesenchymal Stem Cells (MSCs) have a high differentiation potential and can be differentiated in multiple directions. It has wide clinical application prospect in the aspects of tissue engineering such as bones, cartilages, muscles, tendons, ligaments, nerves, livers, endothelia, cardiac muscles and the like. It has been reported that MSCs are separated from human umbilical cord, and the cell content and proliferation ability are superior to bone marrow MSCs, and the immunogenicity is lower than that of bone marrow MSCs, and the method has the advantages of easily available materials, no ethical dispute, and the like, and thus has been receiving more and more attention from researchers. The main uses of umbilical cord mesenchymal stem cells include: the medicine has stronger immunoregulation function, can be used for treating autoimmune diseases such as lupus erythematosus and scleroderma, reducing the immunological rejection reaction after cell or organ transplantation, and improving the success rate of cell or organ transplantation; the hematopoietic recovery function can be promoted, and compared with single hematopoietic stem cell transplantation, the mesenchymal stem cell and hematopoietic stem cell co-transplantation can remarkably improve the treatment effect of diseases such as leukemia, refractory anemia and the like; can repair damaged or diseased tissues and organs, and can be used for treating degenerative diseases of bone and muscle, cardiovascular and cerebrovascular diseases, liver diseases, brain and spinal nerve injury, senile dementia, etc. A typical isolated culture method of umbilical cord mesenchymal stem cells comprises the steps of taking a fresh healthy umbilical cord, washing the umbilical cord with PBS, removing blood vessels with scissors and forceps, peeling off Fahrenheit glue tissues in the umbilical cord mesenchymal stem cells, fully shearing the obtained tissues, adding alpha-MEM culture solution, and culturing in a 5% CO2 culture box at 37 ℃, wherein the culture solution contains 10% FBS, 100U/ml penicillin and 100U/ml streptomycin. After the umbilical cord tissue is cultured for 5-7 days, part of cells climb out from the periphery of the tissue block and are in a fine spindle shape, after one week, the cells begin to rapidly proliferate to form cell colonies with different sizes, and after the cells grow full, the cells are digested by 0.25% trypsin for passage.
The prior art discloses a plurality of culture methods related to the isolated culture of umbilical cord mesenchymal stem cells. For example, CN102965338A (application No. 2012105103791) discloses a method for extracting and culturing human umbilical cord mesenchymal stem cells. After being minced, the umbilical cord tissue is digested by collagenase I and then transferred into a culture flask containing a culture medium for continuous culture. The culture medium is low-sugar DMEM basic culture medium and is added with fetal calf serum, fibroblast growth factor, epithelial cell growth factor, cell transcription factor and cholesterol. The extraction and culture method of the invention can be used for culturing the human umbilical cord mesenchymal stem cells for a long time and maintaining the activity of the stem cells. The invention is believed to solve the problems of too rapid cell aging and differentiation in the conventional culture of human umbilical cord mesenchymal stem cells, and can obtain the human umbilical cord mesenchymal stem cells with the characteristics of stem cells for a long time.
CN103421739A (application No. 2013101962521) provides a simple and efficient method for separating umbilical cord mesenchymal stem cells, which comprises the following steps: isolating umbilical cord mesenchymal stem cells using a cannula and culturing the umbilical cord mesenchymal stem cells using trypLETM digestion and serum-free medium. The umbilical cord mesenchymal stem cells completely from a parent body can be obtained more quickly, and the damage to the cells is smaller; experiments prove that the method can protect the mesenchymal stem cells to the greatest extent, has higher activity rate and higher activity, and can more effectively perform adipogenic and osteogenic induced differentiation.
CN104232573A (application No. 2014104597914) discloses a growth medium for culturing stem cells, which contains a basal medium and an additive containing an antibody against human vascular endothelial growth factor, an antibody against human epidermal growth factor receptor 1, an antibody against human epidermal growth factor receptor 2 and guanosine-5-triphosphate trisodium salt. The invention also provides application of the growth medium in culturing the umbilical cord mesenchymal stem cells. The invention also provides a method for culturing umbilical cord mesenchymal stem cells, which comprises the following steps: umbilical cord mesenchymal stem cells were seeded in the growth medium as described above for culture. Through the technical scheme, the invention is believed to greatly improve the in-vitro amplification capacity of the umbilical cord mesenchymal stem cells.
CN105112365A (application number: 2015105051216) provides a serum-free culture medium for human umbilical cord mesenchymal stem cells, which belongs to the technical field of stem cells, and comprises a DMEM basic culture medium and also comprises the following components: recombinant human insulin, human serum albumin, transferrin, fibronectin, vitamin C, biotin, stem cell growth factor and stem cell factor. The serum-free culture medium for the human umbilical cord mesenchymal stem cells provided by the invention is free from culture bottle coating, is simple and convenient to operate, has a high cell proliferation rate, maintains good stem cell juvenile form and stem cell characteristics, has good cell induced differentiation potential, and reduces the cost.
CN105112360A (application No. 2015104231387) provides a mass culture method of umbilical cord mesenchymal stem cells, which comprises the following steps: obtaining the Wharton jelly of the umbilical cord; carrying out P0 subculture on the Wharton jelly of the umbilical cord until the cell fusion degree is 40-50%, and then carrying out P1 subculture until the cell fusion degree is 85-95%; inoculating and culturing the P1 generation cells in a plate culture medium, and separating suspension cells which are not adhered by the plate culture medium; the suspension cells were cultured in culture medium containing leukemia inhibitory factor and fibroblast-like growth factor for P2 passages. According to the tissue adherent culture method, the P0 cells with low early-stage multidirectional change are directly cultured to the P1 generation, and then the tissue culture plate is used for adhesion screening, so that the uniformity of the differentiation degree of the cells is kept; and then increasing the adherence performance of the cells in the culture of P2 generation by using leukemia inhibitory factor and fibroblast-like growth factor and inhibiting differentiation, thereby obtaining the umbilical cord mesenchymal stem cells with lower and consistent differentiation degree and stronger adherence capability and favorable collection.
CN105602893A (2015109956392) discloses a method for serum-free culture of umbilical cord mesenchymal stem cells, comprising the following steps: (1) preparing a coating solution of fibronectin, recombinant human epidermal growth factor and recombinant human fibroblast growth factor, and coating a plastic culture bottle; (2) taking human umbilical cord tissue Walton's gum, shearing, and adding into the step (1); (3) adding a serum-free culture medium into the obtained product in the step (2); (4) culturing in a 5% carbon dioxide incubator at 37 deg.C for 10-12 days to obtain mesenchymal stem cells; (5) washing with phosphate buffer solution and digesting with Triple enzyme; (6) adding phosphate buffer solution to stop digestion; (7) collecting mesenchymal stem cell supernatant; (8) centrifuging; (9) collecting the precipitate to obtain the required mesenchymal stem cells. According to the method disclosed by the invention, the mesenchymal cells can be passaged for 20 generations, the characteristics of the mesenchymal stem cells are maintained, diseases can be treated, and the method has an application prospect.
CN106399237A (application number: 2016110843258) discloses a primary isolation method of umbilical cord mesenchymal stem cells. Obtaining the Wharton's jelly from an umbilical cord, mixing the Wharton's jelly with a DMEM/F12 culture medium containing 20% FBS, crisscross grinding in a mortar for 30-50 rounds, pausing for 15s every 10 rounds, and collecting the Wharton's jelly again; and (3) resuspending the ground Wharton's jelly by using a culture medium, filtering, and culturing the filtrate in the culture medium until mesenchymal stem cells are obtained. According to the invention, the specific grinding mode and frequency are used for replacing the scissors in the tissue block adherent culture method to cut, so that the aim of rapidly processing the umbilical cord tissue is achieved, the appearance time of the creeping-out cells is obviously shortened, the multiplication capacity of the passage cells is not influenced, and the primary separation efficiency of the umbilical cord mesenchymal stem cells is integrally improved.
CN107653226A (application number: 2017111313893) relates to a method for separating and culturing human umbilical cord mesenchymal stem cells, which comprises the following steps: taking an in-vitro umbilical cord of a fetus born by a full-term cesarean section, and placing the umbilical cord into sterile tissue preservation solution for preservation; flushing with normal saline for several times to remove residual blood stain; removing two umbilical veins and two umbilical arteries of the tissue block by using a pair of forceps with teeth, and completely cutting the huatong glue into pieces by using sterile scissors; transferring the cut Huatong glue into a culture medium, oscillating and centrifuging; transferring the centrifuged pellet fraction to a cell culture flask; culturing for 5-6 days, allowing part of cells to climb out from the small tissue blocks, replacing the culture medium every 3 days, and continuously culturing; the cell fusion degree reaches more than 80% at about 14 days, and the cells grow in a vortex manner; then, sufficient mesenchymal stem cells can be obtained every 3 days. The invention is believed to be easier and higher in stem cell purity and yield than traditional tissue block methods.
Although the prior art discloses some culture methods such as those described above in relation to umbilical cord mesenchymal stem cells, these methods often require the use of a medium containing a relatively high concentration of fetal bovine serum.
It is still expected to provide a new method for isolated culture or even subculture of mesenchymal stem cells, and in particular to provide a new method without fetal calf serum for isolated culture or even subculture of mesenchymal stem cells.
Disclosure of Invention
The invention aims to provide a novel method for preparing umbilical cord mesenchymal stem cells, in particular to provide a method suitable for separating and obtaining umbilical cord mesenchymal stem cells from umbilical cords and a method for passaging the obtained stem cells, and the method is expected to show the characteristics of high cell yield, high cell survival rate and the like and/or other excellent performances. The present inventors have surprisingly found that the technical effects of one or more aspects as described herein can be obtained using the process of the present invention. The present invention has been completed based on this finding.
To this end, the invention provides in a first aspect a method for isolated culture of primary umbilical cord mesenchymal stem cells, comprising the steps of:
(1) treating the umbilical cord sample transported to a laboratory through a cold chain at 2-8 ℃ in a biosafety cabinet;
(2) D-Hanks is fully cleaned to remove surface bloodiness, the umbilical cord is cut into small sections by using a surgical scissors, the small sections are placed in a plate, the small sections are repeatedly squeezed by using surgical forceps, residual blood clots in tissues are removed, and the umbilical cord is cleaned by using the D-Hanks;
(3) cutting tissue, peeling off epidermis, removing artery and vein to obtain tissue of Wharton jelly, cutting Wharton jelly into small pieces, and weighing;
(4) inoculating the tissue to a culture bottle according to a specified tissue quantity, adding a primary complete culture medium, fully and uniformly mixing to enable tissue blocks to be uniformly spread on the bottom of the bottle, and culturing in a CO2 culture box;
(5) and (3) culturing until the complete culture medium is supplemented in the 3 rd step, continuously culturing until the primary complete culture medium is supplemented in the 5 th step, continuously culturing until the liquid is completely changed in the 7 th step, removing the old culture medium after the cell fusion degree reaches more than 80%, cleaning the cells by using D-hanks liquid, adding recombinant pancreatin solution to digest the cells to make the cells fall off, adding the D-hanks liquid to dilute, centrifuging, and re-suspending the cell precipitate by using the primary complete culture medium to obtain the primary umbilical cord mesenchymal stem cells (namely P0 generation).
The method according to the first aspect of the present invention, wherein in the step (3), the gordonia gel is cut into 0.25cm2Small pieces of size.
The method according to the first aspect of the present invention, wherein the step (4) of inoculating the tissue mass into the culture flask according to the predetermined tissue mass means that 1.5g of the tissue mass of Wharton jelly obtained in the step (3) is weighed and inoculated into a T225 culture flask.
The method according to the first aspect of the present invention, wherein in step (4), 15ml of primary complete culture medium is added to each bottle, the mixture is thoroughly mixed, the tissue blocks are evenly spread on the bottom of the bottle, and the bottle is placed in a CO2 incubator for culture.
The process according to the first aspect of the present invention, wherein in the step (4), CO2The conditions for the culture in the incubator were: 5% CO2At 37 deg.C, saturated humidity.
The method according to the first aspect of the present invention, wherein in step (5), the culture is continued until 3d supplemented with 10ml of primary complete medium.
The method according to the first aspect of the present invention, wherein in step (5), the culture is continued until 5d supplemented with 10ml of primary complete medium.
The method according to the first aspect of the present invention, wherein in the step (5), 5ml of the recombinant pancreatin solution is added per vial for digesting the cells for 2 min.
The process according to the first aspect of the present invention, wherein in step (5), 25ml of D-hanks solution is added per bottle for dilution.
The method according to the first aspect of the present invention, wherein in step (5), the centrifugation is carried out at 100Xg for 10 min.
The method according to the first aspect of the present invention, wherein the formulation of the D-Hanks liquid is as follows: 8.0g NaCl, 0.4g KCl, 0.06g KH2PO4, 0.08g Na2HPO4.12H2O, 0.35g NaHCO3, water to 1000 ml. For example, the preparation method is as follows: dissolving the materials in 1000ml, and filtering with 0.22 μm microporous membrane for sterilization.
The method according to the first aspect of the invention, wherein said primary complete medium is prepared with DMEM-F12 medium as a matrix and comprises: 0.8% platelet lysate, 1% human serum albumin, 2. mu.g/ml recombinant insulin, 15ng/ml EGF, 25ng/ml bFGF.
The method according to the first aspect of the invention, wherein said primary complete medium is replaced by primary supplemented medium. The method according to the first aspect of the invention, wherein said primary supplementary medium is formulated in DMEM-F12 medium as a medium and comprises: 0.8% platelet lysate, 1% human serum albumin, 2. mu.g/ml recombinant insulin, 15ng/ml EGF, 25ng/ml bFGF, 0.1% thioglycerol, 1% fructose.
The method according to the first aspect of the present invention, wherein said DMEM-F12 medium formula consists of: 116.6mg of anhydrous calcium chloride, 59.05mg of L-leucine, 0.042mg of linoleic acid, 0.0013mg of copper sulfate pentahydrate, 91.25mg of L-lysine hydrochloride, 0.105mg of lipoic acid, 0.05mg of ferric nitrate nonahydrate, 17.24mg of L-methionine, 8.1mg of phenol red, 0.417mg of ferrous sulfate heptahydrate, 35.48mg of L-phenylalanine, 0.081mg of 1, 4-butanediamine dihydrochloride, 311.8mg of potassium chloride, 26.25mg of L-serine, 55mg of sodium pyruvate, 28.64mg of magnesium chloride, 53.45mg of L-threonine, 0.0035mg of vitamin H, 48.84mg of anhydrous magnesium sulfate, 4.45mg of L-alanine, 2.24mg of D-calcium pantothenate, 7000mg of sodium chloride, 7.5mg of L-asparagine, 8.98mg of choline chloride, 54.35mg of anhydrous sodium dihydrogen phosphate, 6.65mg of L-aspartic acid, 2.65mg of L-cysteine, 56.52 mg of L-disodium hydrogen phosphate, 17.12 mg of L-17 mg of inositol phosphate, 6.52 mg of L-asparagine, 0.432mg of zinc sulfate heptahydrate, 7.35mg of L-glutamic acid, 2.02mg of nicotinamide, 147.5mg of L-arginine hydrochloride, 17.25mg of L-proline, 2mg of pyridoxal hydrochloride, 31.29mg of L-cystine hydrochloride, 9.02mg of L-tryptophan, 0.031mg of pyridoxine hydrochloride, 365mg of L-glutamine, 38.4mg of L-tyrosine, 0.219mg of riboflavin, 18.75mg of glycine, 52.85mg of L-valine, 2.17mg of thiamine hydrochloride, 31.48mg of L-histidine hydrochloride, 3151mg of D-glucose, 0.365mg of thymidine, 54.47mg of L-isoleucine, 2mg of hypoxanthine, 0.68mg of vitamin B12 and adding a proper amount of water to 1000 mL; preparation: dissolving the materials in 1000ml, and filtering with 0.22 μm microporous membrane for sterilization.
The method according to the first aspect of the present invention, further comprising detecting the primary umbilical cord mesenchymal stem cells obtained by isolated culture. For example, detection of cell morphology and/or immunophenotypic identification. In one embodiment, said immunophenotypic identification refers to detection of CD73, CD90, CD105 and CD19, CD11b, CD31, CD45, HLADR, CD 34. The primary umbilical cord mesenchymal stem cells obtained by the method are positive in CD73, CD90 and CD105 (all more than 98%), and negative in CD19, CD11b, CD31, CD45, HLADR and CD34 (all less than 2%).
Further, the present invention provides in a second aspect a method for isolating and subculturing umbilical cord mesenchymal stem cells, which comprises two stages of (a) isolating and culturing primary umbilical cord mesenchymal stem cells and (b) subculturing umbilical cord mesenchymal stem cells, wherein
(a) The stage of separating and culturing the primary umbilical cord mesenchymal stem cells comprises the following steps:
(a1) treating the umbilical cord sample transported to a laboratory through a cold chain at 2-8 ℃ in a biosafety cabinet;
(a2) D-Hanks is fully cleaned to remove surface bloodiness, the umbilical cord is cut into small sections by using a surgical scissors, the small sections are placed in a plate, the small sections are repeatedly squeezed by using surgical forceps, residual blood clots in tissues are removed, and the umbilical cord is cleaned by using the D-Hanks;
(a3) cutting tissue, peeling off epidermis, removing artery and vein to obtain tissue of Wharton jelly, cutting Wharton jelly into small pieces, and weighing;
(a4) inoculating the tissue to a culture bottle according to a specified tissue quantity, adding a primary complete culture medium, fully and uniformly mixing to enable tissue blocks to be uniformly spread on the bottom of the bottle, and culturing in a CO2 culture box;
(a5) culturing until the 3 rd supplemented complete culture medium is continuously cultured, continuing culturing until the 5 th supplemented primary complete culture medium is continuously cultured, completely replacing the culture solution until the 7 th cell fusion degree reaches more than 80%, removing the old culture medium, cleaning the cells by using D-hanks liquid, adding recombinant pancreatin solution to digest the cells to make the cells fall off, adding the D-hanks liquid to dilute, centrifuging, and re-suspending the cell precipitate by using the primary complete culture medium to obtain primary umbilical cord mesenchymal stem cells (namely P0 generation);
(b) the stage of subculturing the umbilical cord mesenchymal stem cells comprises the following steps:
(b1) inoculating primary (namely P0 generation) mesenchymal stem cells into a T225 bottle according to the density of 5000/cm2, supplementing a passage complete culture medium to 45ml, placing the bottle in a CO2 incubator (5% CO2, 37 ℃, saturation humidity) to culture until the cell fusion degree reaches 70-80% (generally reaching on the 3 rd day), abandoning the old culture medium, cleaning the cells by using a D-hanks solution, adding 5ml of a recombinant pancreatin solution into each bottle for digesting the cells for 2min to ensure that the cells fall off, adding 15ml of the D-hanks solution into each bottle for diluting, combining all cell suspensions into a 50ml centrifugal tube, centrifuging, precipitating the cells by using the passage complete culture medium to obtain the P1 generation mesenchymal stem cells, and then sampling to perform cell counting and activity rate measurement;
(b2) inoculating the mesenchymal stem cells of the P1 generation into a T225 bottle according to the density of 5000/cm2, supplementing a complete subculture medium to 45ml, putting the bottle in a CO2 incubator (5% CO2, 37 ℃, and saturation humidity), and carrying out subculture according to a P1 subculture method to obtain the mesenchymal stem cells of the P2 generation; then, the cells are continuously passaged to the P10 generation by the method of the above P1 generation and P2 generation, and mesenchymal stem cells of each generation are obtained.
The method according to the second aspect of the present invention, wherein in the step (a3), the gordonia gel is cut into 0.25cm2Small pieces of size.
The method according to the second aspect of the present invention, wherein the inoculation into the culture flask in the prescribed tissue amount in step (a4) means that 1.5g of the tissue piece of Wharton's jelly obtained in step (3) is weighed and inoculated into a T225 culture flask.
The method according to the second aspect of the present invention, wherein in the step (a4), 15ml of primary complete medium is added to each bottle, sufficiently mixed, and the tissue pieces are uniformly spread on the bottom of the bottle, and cultured in a CO2 incubator.
The method according to the second aspect of the present invention, wherein in the step (a4), CO2The conditions for the culture in the incubator were: 5% CO2At 37 deg.C, saturated humidity.
The method according to the second aspect of the present invention, wherein in step (a5), the culture is continued until 3d is supplemented with 10ml of primary complete medium.
The method according to the second aspect of the present invention, wherein in step (a5), the culture is continued until 5d is supplemented with 10ml of primary complete medium.
The method according to the second aspect of the present invention, wherein in the step (a5), 5ml of the recombinant pancreatin solution is added per vial for digesting the cells for 2 min.
The process according to the second aspect of the present invention, wherein in step (a5), 25ml of D-hanks solution is added per bottle for dilution.
The method according to the second aspect of the present invention, wherein in the step (a5), the centrifugation is performed at 100Xg for 10 min.
The method according to the second aspect of the present invention, wherein the formulation of the D-Hanks liquid is as follows: 8.0g NaCl, 0.4g KCl, 0.06g KH2PO4, 0.08g Na2HPO4.12H2O, 0.35g NaHCO3, water to 1000 ml. For example, the preparation method is as follows: dissolving the materials in 1000ml, and filtering with 0.22 μm microporous membrane for sterilization.
The method according to the second aspect of the invention, wherein said primary complete medium is prepared with DMEM-F12 medium as a matrix and comprises: 0.8% platelet lysate, 1% human serum albumin, 2. mu.g/ml recombinant insulin, 15ng/ml EGF, 25ng/ml bFGF.
The method according to the second aspect of the invention, wherein said primary complete medium is replaced by primary supplemented medium. The method according to the second aspect of the invention, wherein said primary supplementary medium is formulated in DMEM-F12 medium as a medium and comprises: 0.8% platelet lysate, 1% human serum albumin, 2. mu.g/ml recombinant insulin, 15ng/ml EGF, 25ng/ml bFGF, 0.1% thioglycerol, 1% fructose.
The method according to the second aspect of the present invention, wherein the DMEM-F12 medium formulation consists of: 116.6mg of anhydrous calcium chloride, 59.05mg of L-leucine, 0.042mg of linoleic acid, 0.0013mg of copper sulfate pentahydrate, 91.25mg of L-lysine hydrochloride, 0.105mg of lipoic acid, 0.05mg of ferric nitrate nonahydrate, 17.24mg of L-methionine, 8.1mg of phenol red, 0.417mg of ferrous sulfate heptahydrate, 35.48mg of L-phenylalanine, 0.081mg of 1, 4-butanediamine dihydrochloride, 311.8mg of potassium chloride, 26.25mg of L-serine, 55mg of sodium pyruvate, 28.64mg of magnesium chloride, 53.45mg of L-threonine, 0.0035mg of vitamin H, 48.84mg of anhydrous magnesium sulfate, 4.45mg of L-alanine, 2.24mg of D-calcium pantothenate, 7000mg of sodium chloride, 7.5mg of L-asparagine, 8.98mg of choline chloride, 54.35mg of anhydrous sodium dihydrogen phosphate, 6.65mg of L-aspartic acid, 2.65mg of L-cysteine, 56.52 mg of L-disodium hydrogen phosphate, 17.12 mg of L-17 mg of inositol phosphate, 6.52 mg of L-asparagine, 0.432mg of zinc sulfate heptahydrate, 7.35mg of L-glutamic acid, 2.02mg of nicotinamide, 147.5mg of L-arginine hydrochloride, 17.25mg of L-proline, 2mg of pyridoxal hydrochloride, 31.29mg of L-cystine hydrochloride, 9.02mg of L-tryptophan, 0.031mg of pyridoxine hydrochloride, 365mg of L-glutamine, 38.4mg of L-tyrosine, 0.219mg of riboflavin, 18.75mg of glycine, 52.85mg of L-valine, 2.17mg of thiamine hydrochloride, 31.48mg of L-histidine hydrochloride, 3151mg of D-glucose, 0.365mg of thymidine, 54.47mg of L-isoleucine, 2mg of hypoxanthine, 0.68mg of vitamin B12 and adding a proper amount of water to 1000 mL; preparation: dissolving the materials in 1000ml, and filtering with 0.22 μm microporous membrane for sterilization.
The method according to the second aspect of the present invention, further comprising detecting the primary umbilical cord mesenchymal stem cells obtained by isolated culture. For example, detection of cell morphology and/or immunophenotypic identification. In one embodiment, said immunophenotypic identification refers to detection of CD73, CD90, CD105 and CD19, CD11b, CD31, CD45, HLADR, CD 34. The primary umbilical cord mesenchymal stem cells obtained by the method are positive in CD73, CD90 and CD105 (all more than 98%), and negative in CD19, CD11b, CD31, CD45, HLADR and CD34 (all less than 2%).
In the context of the present invention, reference is made to a complete subculture medium which is formulated with DMEM-F12 medium as the matrix and comprises: 2% platelet lysate, 1% human serum albumin, 2. mu.g/ml recombinant insulin, 10ng/ml EGF, 15ng/ml bFGF, 0.035% thioglycerol, 1% fructose.
Further, the third aspect of the present invention provides a culture medium for isolated culture of mesenchymal stem cells, which may also be referred to as primary complete culture medium, prepared by using DMEM-F12 as a matrix and comprising: 0.8% platelet lysate, 1% human serum albumin, 2. mu.g/ml recombinant insulin, 15ng/ml EGF, 25ng/ml bFGF.
The culture medium according to the third aspect of the present invention is prepared using DMEM-F12 medium as a medium and comprises: 0.8% platelet lysate, 1% human serum albumin, 2. mu.g/ml recombinant insulin, 15ng/ml EGF, 25ng/ml bFGF, 0.1% thioglycerol, 1% fructose. The primary complete medium comprising thioglycerol and fructose may also be referred to as primary supplemented medium.
The culture medium according to the third aspect of the present invention, wherein the isolated culture of mesenchymal stem cells is carried out according to a method comprising the steps of:
(1) treating the umbilical cord sample transported to a laboratory through a cold chain at 2-8 ℃ in a biosafety cabinet;
(2) D-Hanks is fully cleaned to remove surface bloodiness, the umbilical cord is cut into small sections by using a surgical scissors, the small sections are placed in a plate, the small sections are repeatedly squeezed by using surgical forceps, residual blood clots in tissues are removed, and the umbilical cord is cleaned by using the D-Hanks;
(3) cutting tissue, peeling off epidermis, removing artery and vein to obtain tissue of Wharton jelly, cutting Wharton jelly into small pieces, and weighing;
(4) inoculating the tissue to a culture bottle according to a specified tissue quantity, adding a primary complete culture medium, fully and uniformly mixing to enable tissue blocks to be uniformly spread on the bottom of the bottle, and culturing in a CO2 culture box;
(5) and (3) culturing until the complete culture medium is supplemented in the 3 rd step, continuously culturing until the primary complete culture medium is supplemented in the 5 th step, continuously culturing until the liquid is completely changed in the 7 th step, removing the old culture medium after the cell fusion degree reaches more than 80%, cleaning the cells by using D-hanks liquid, adding recombinant pancreatin solution to digest the cells to make the cells fall off, adding the D-hanks liquid to dilute, centrifuging, and re-suspending the cell precipitate by using the primary complete culture medium to obtain the primary umbilical cord mesenchymal stem cells (namely P0 generation).
The culture medium according to the third aspect of the present invention, wherein in the step (3) of isolated culture of mesenchymal stem cells, Wharton's jelly is cut into 0.25cm2Small pieces of size.
The culture medium according to the third aspect of the present invention, wherein in the step (4) of isolated culture of mesenchymal stem cells, the step of inoculating into the culture flask according to the specified tissue quantity means that 1.5g of the tissue pieces of Wharton jelly obtained in the step (3) are weighed and inoculated into a T225 culture flask.
The culture medium according to the third aspect of the present invention, wherein in the step (4) of mesenchymal stem cell isolation and culture, 15ml of primary complete culture medium is added into each bottle, the mixture is fully mixed, so that the tissue mass is uniformly spread on the bottom of the bottle, and the bottle is placed in a CO2 incubator for culture.
The medium according to the third aspect of the present invention, wherein in the step (4) of isolated culture of mesenchymal stem cells, CO2The conditions for the culture in the incubator were: 5% CO2At 37 deg.C, saturated humidity.
The culture medium according to the third aspect of the present invention, wherein in the step (5) of isolated culture of mesenchymal stem cells, the culture is continued until the 3 rd supplement with 10ml of primary complete culture medium.
The culture medium according to the third aspect of the present invention, wherein in the step (5) of isolated culture of mesenchymal stem cells, the culture is continued until the 5 th day supplemented with 10ml of primary complete medium.
The medium according to the third aspect of the present invention, wherein in the step (5) of the isolated culture of mesenchymal stem cells, 5ml of the recombinant pancreatin solution is added per bottle for digesting the cells for 2 min.
The culture medium according to the third aspect of the present invention, wherein in the step (5) of isolated culture of mesenchymal stem cells, 25ml of D-hanks solution is added per bottle for dilution.
The medium according to the third aspect of the present invention, wherein the mesenchymal stem cells are centrifuged at 100Xg for 10min in the step (5) of the isolated culture.
The culture medium according to the third aspect of the present invention, wherein the mesenchymal stem cell isolation culture is the formula composition of the D-Hanks liquid as follows: 8.0g NaCl, 0.4g KCl, 0.06g KH2PO4, 0.08g Na2HPO4.12H2O, 0.35g NaHCO3, water to 1000 ml. For example, the preparation method is as follows: dissolving the materials in 1000ml, and filtering with 0.22 μm microporous membrane for sterilization.
The culture medium according to the third aspect of the present invention, wherein the DMEM-F12 medium has the following formula: 116.6mg of anhydrous calcium chloride, 59.05mg of L-leucine, 0.042mg of linoleic acid, 0.0013mg of copper sulfate pentahydrate, 91.25mg of L-lysine hydrochloride, 0.105mg of lipoic acid, 0.05mg of ferric nitrate nonahydrate, 17.24mg of L-methionine, 8.1mg of phenol red, 0.417mg of ferrous sulfate heptahydrate, 35.48mg of L-phenylalanine, 0.081mg of 1, 4-butanediamine dihydrochloride, 311.8mg of potassium chloride, 26.25mg of L-serine, 55mg of sodium pyruvate, 28.64mg of magnesium chloride, 53.45mg of L-threonine, 0.0035mg of vitamin H, 48.84mg of anhydrous magnesium sulfate, 4.45mg of L-alanine, 2.24mg of D-calcium pantothenate, 7000mg of sodium chloride, 7.5mg of L-asparagine, 8.98mg of choline chloride, 54.35mg of anhydrous sodium dihydrogen phosphate, 6.65mg of L-aspartic acid, 2.65mg of L-cysteine, 56.52 mg of L-disodium hydrogen phosphate, 17.12 mg of L-17 mg of inositol phosphate, 6.52 mg of L-asparagine, 0.432mg of zinc sulfate heptahydrate, 7.35mg of L-glutamic acid, 2.02mg of nicotinamide, 147.5mg of L-arginine hydrochloride, 17.25mg of L-proline, 2mg of pyridoxal hydrochloride, 31.29mg of L-cystine hydrochloride, 9.02mg of L-tryptophan, 0.031mg of pyridoxine hydrochloride, 365mg of L-glutamine, 38.4mg of L-tyrosine, 0.219mg of riboflavin, 18.75mg of glycine, 52.85mg of L-valine, 2.17mg of thiamine hydrochloride, 31.48mg of L-histidine hydrochloride, 3151mg of D-glucose, 0.365mg of thymidine, 54.47mg of L-isoleucine, 2mg of hypoxanthine, 0.68mg of vitamin B12 and adding a proper amount of water to 1000 mL; preparation: dissolving the materials in 1000ml, and filtering with 0.22 μm microporous membrane for sterilization.
The culture medium according to the third aspect of the present invention, wherein the step of isolated culture of mesenchymal stem cells further comprises detecting the primary umbilical cord mesenchymal stem cells obtained from the isolated culture. For example, detection of cell morphology and/or immunophenotypic identification. In one embodiment, said immunophenotypic identification refers to detection of CD73, CD90, CD105 and CD19, CD11b, CD31, CD45, HLADR, CD 34. The primary umbilical cord mesenchymal stem cells obtained by the method are positive in CD73, CD90 and CD105 (all more than 98%), and negative in CD19, CD11b, CD31, CD45, HLADR and CD34 (all less than 2%).
Further, in the fourth aspect of the present invention, there is provided a primary umbilical cord mesenchymal stem cell, which is positive for CD73, CD90 and CD105, and negative for CD19, CD11b, CD31, CD45, HLADR and CD34, and is isolated and cultured according to the following steps:
(1) treating the umbilical cord sample transported to a laboratory through a cold chain at 2-8 ℃ in a biosafety cabinet;
(2) D-Hanks is fully cleaned to remove surface bloodiness, the umbilical cord is cut into small sections by using a surgical scissors, the small sections are placed in a plate, the small sections are repeatedly squeezed by using surgical forceps, residual blood clots in tissues are removed, and the umbilical cord is cleaned by using the D-Hanks;
(3) cutting tissue, peeling off epidermis, removing artery and vein to obtain tissue of Wharton jelly, cutting Wharton jelly into small pieces, and weighing;
(4) inoculating the tissue to a culture bottle according to a specified tissue quantity, adding a primary complete culture medium, fully and uniformly mixing to enable tissue blocks to be uniformly spread on the bottom of the bottle, and culturing in a CO2 culture box;
(5) and (3) culturing until the complete culture medium is supplemented in the 3 rd step, continuously culturing until the primary complete culture medium is supplemented in the 5 th step, continuously culturing until the liquid is completely changed in the 7 th step, removing the old culture medium after the cell fusion degree reaches more than 80%, cleaning the cells by using D-hanks liquid, adding recombinant pancreatin solution to digest the cells to make the cells fall off, adding the D-hanks liquid to dilute, centrifuging, and re-suspending the cell precipitate by using the primary complete culture medium to obtain the primary umbilical cord mesenchymal stem cells (namely P0 generation).
The primary umbilical cord mesenchymal stem cells according to the fourth aspect of the present invention, wherein in step (3), the Wharton's jelly is cut into 0.25cm2Small pieces of size.
The primary umbilical cord mesenchymal stem cells according to the fourth aspect of the present invention, wherein the step (4) of inoculating into the culture flask according to the specified tissue quantity means that 1.5g of the tissue piece of Wharton jelly obtained in the step (3) is weighed and inoculated into a T225 culture flask.
According to the primary umbilical cord mesenchymal stem cells of the fourth aspect of the invention, in the step (4), 15ml of primary complete culture medium is added into each bottle, the mixture is fully and uniformly mixed, so that the tissue blocks are uniformly spread on the bottom of the bottle, and the bottle is placed in a CO2 incubator for culture.
The primary umbilical cord mesenchymal stem cells according to the fourth aspect of the present invention, wherein in step (4), the CO2The conditions for the culture in the incubator were: 5% CO2At 37 deg.C, saturated humidity.
The primary umbilical cord mesenchymal stem cells according to the fourth aspect of the present invention, wherein in the step (5), the culture is continued until the 3 rd supplement with 10ml of primary complete medium.
The primary umbilical cord mesenchymal stem cells according to the fourth aspect of the present invention, wherein in the step (5), the culture is continued until the 5 th d supplemented with 10ml of primary complete medium.
The primary umbilical cord mesenchymal stem cells according to the fourth aspect of the present invention, wherein in the step (5), 5ml of the recombinant pancreatin solution is added per bottle for digesting the cells for 2 min.
The primary umbilical cord mesenchymal stem cells according to the fourth aspect of the invention, wherein in the step (5), 25ml of D-hanks solution is added to each bottle for dilution.
The primary umbilical cord mesenchymal stem cells according to the fourth aspect of the present invention, wherein in step (5), the cells are centrifuged at 100Xg for 10 min.
The primary umbilical cord mesenchymal stem cells according to the fourth aspect of the invention, wherein the formula of the D-Hanks liquid comprises the following components: 8.0g NaCl, 0.4g KCl, 0.06g KH2PO4, 0.08g Na2HPO4.12H2O, 0.35g NaHCO3, water to 1000 ml. For example, the preparation method is as follows: dissolving the materials in 1000ml, and filtering with 0.22 μm microporous membrane for sterilization.
The primary umbilical cord mesenchymal stem cells according to the fourth aspect of the present invention, wherein the primary complete medium is prepared with DMEM-F12 medium as a medium and comprises: 0.8% platelet lysate, 1% human serum albumin, 2. mu.g/ml recombinant insulin, 15ng/ml EGF, 25ng/ml bFGF.
The primary umbilical cord mesenchymal stem cells according to the fourth aspect of the invention, wherein the primary complete medium is replaced with primary supplemented medium. The method according to the first aspect of the invention, wherein said primary supplementary medium is formulated in DMEM-F12 medium as a medium and comprises: 0.8% platelet lysate, 1% human serum albumin, 2. mu.g/ml recombinant insulin, 15ng/ml EGF, 25ng/ml bFGF, 0.1% thioglycerol, 1% fructose.
Further, the fifth aspect of the present invention provides a complete subculture medium for umbilical cord mesenchymal stem cell subculture, which is prepared by taking DMEM-F12 medium as a matrix and comprises: 2% platelet lysate, 1% human serum albumin, 2. mu.g/ml recombinant insulin, 10ng/ml EGF, 15ng/ml bFGF, 0.035% thioglycerol, 1% fructose.
The passaging complete medium according to the fifth aspect of the present invention, which is used in the method for isolation culture and subculture of umbilical cord mesenchymal stem cells, comprises two stages of (a) isolation culture of primary umbilical cord mesenchymal stem cells and (b) subculture of umbilical cord mesenchymal stem cells, wherein
(a) The stage of separating and culturing the primary umbilical cord mesenchymal stem cells comprises the following steps:
(a1) treating the umbilical cord sample transported to a laboratory through a cold chain at 2-8 ℃ in a biosafety cabinet;
(a2) D-Hanks is fully cleaned to remove surface bloodiness, the umbilical cord is cut into small sections by using a surgical scissors, the small sections are placed in a plate, the small sections are repeatedly squeezed by using surgical forceps, residual blood clots in tissues are removed, and the umbilical cord is cleaned by using the D-Hanks;
(a3) cutting tissue, peeling off epidermis, removing artery and vein to obtain tissue of Wharton jelly, cutting Wharton jelly into small pieces, and weighing;
(a4) inoculating the tissue to a culture bottle according to a specified tissue quantity, adding a primary complete culture medium, fully and uniformly mixing to enable tissue blocks to be uniformly spread on the bottom of the bottle, and culturing in a CO2 culture box;
(a5) culturing until the 3 rd supplemented complete culture medium is continuously cultured, continuing culturing until the 5 th supplemented primary complete culture medium is continuously cultured, completely replacing the culture solution until the 7 th cell fusion degree reaches more than 80%, removing the old culture medium, cleaning the cells by using D-hanks liquid, adding recombinant pancreatin solution to digest the cells to make the cells fall off, adding the D-hanks liquid to dilute, centrifuging, and re-suspending the cell precipitate by using the primary complete culture medium to obtain primary umbilical cord mesenchymal stem cells (namely P0 generation);
(b) the stage of subculturing the umbilical cord mesenchymal stem cells comprises the following steps:
(b1) inoculating primary (namely P0 generation) mesenchymal stem cells into a T225 bottle according to the density of 5000/cm2, supplementing a passage complete culture medium to 45ml, placing the bottle in a CO2 incubator (5% CO2, 37 ℃, saturation humidity) to culture until the cell fusion degree reaches 70-80% (generally reaching on the 3 rd day), abandoning the old culture medium, cleaning the cells by using a D-hanks solution, adding 5ml of a recombinant pancreatin solution into each bottle for digesting the cells for 2min to ensure that the cells fall off, adding 15ml of the D-hanks solution into each bottle for diluting, combining all cell suspensions into a 50ml centrifugal tube, centrifuging, precipitating the cells by using the passage complete culture medium to obtain the P1 generation mesenchymal stem cells, and then sampling to perform cell counting and activity rate measurement;
(b2) inoculating the mesenchymal stem cells of the P1 generation into a T225 bottle according to the density of 5000/cm2, supplementing a complete subculture medium to 45ml, putting the bottle in a CO2 incubator (5% CO2, 37 ℃, and saturation humidity), and carrying out subculture according to a P1 subculture method to obtain the mesenchymal stem cells of the P2 generation; then, the cells are continuously passaged to the P10 generation by the method of the above P1 generation and P2 generation, and mesenchymal stem cells of each generation are obtained.
According to the sixth aspect of the invention, the serum-free medium is used for separating umbilical cord mesenchymal stem cells, and the serum-free medium (which can also be called primary supplementary medium) is prepared by taking DMEM-F12 as a matrix and comprises: 0.8% platelet lysate, 1% human serum albumin, 2. mu.g/ml recombinant insulin, 15ng/ml EGF, 25ng/ml bFGF, 0.1% thioglycerol, 1% fructose.
According to the seventh aspect of the invention, the serum-free medium is used for passaging umbilical cord mesenchymal stem cells, and the serum-free medium (which can also be called passage complete medium) is prepared by taking DMEM-F12 as a medium and comprises: 2% platelet lysate, 1% human serum albumin, 2. mu.g/ml recombinant insulin, 10ng/ml EGF, 15ng/ml bFGF, 0.035% thioglycerol, 1% fructose.
In the present invention, "10 ^ 6" indicates the power of 6 of 10 when indicating the number of cells; in the present invention, "cm ^ 2" represents a square centimeter when representing a culture area; other cases involving "^" symbols, all have similar meanings; the meaning of this symbol is also well known in the art.
Of the various process steps described above, although specific steps are described in some detail or in language specific to the process steps described in the examples of the following detailed description, those skilled in the art will be able to fully appreciate the above-described process steps from the detailed disclosure of the invention as a whole.
Any embodiment of any aspect of the invention may be combined with other embodiments, as long as they do not contradict. Furthermore, in any embodiment of any aspect of the invention, any feature may be applicable to that feature in other embodiments, so long as they do not contradict. The invention is further described below.
All documents cited herein are incorporated by reference in their entirety and to the extent such documents do not conform to the meaning of the present invention, the present invention shall control. Further, the various terms and phrases used herein have the ordinary meaning as is known to those skilled in the art, and even though such terms and phrases are intended to be described or explained in greater detail herein, reference is made to the term and phrase as being inconsistent with the known meaning and meaning as is accorded to such meaning throughout this disclosure.
In the present invention, the term "umbilical cord mesenchymal stem cells" refers to mesenchymal stem cells derived from the umbilical cord. Thus, in the present invention, and in particular in the context relating to the present invention, the term "umbilical cord mesenchymal stem cell" may be used interchangeably with "umbilical cord stem cell", "mesenchymal stem cell", unless otherwise specifically indicated.
In the present invention, the term "PBS buffer" or "PBS" refers to a phosphate buffer. The general formulation and formulation of the PBS used in the context of the present invention, as well as their general properties such as pH value or pH range, are well known to those skilled in the art and are typically commercially available pre-formulations (or powders), e.g. the PBS used in the field of the present invention is typically a commercial buffer at pH7.4(± 0.1), e.g. HyClone brand PBS buffer; in the present invention, the composition of PBS buffer solution in the classical application of the art includes 137mM sodium chloride, 2.7nM potassium chloride and 10mM phosphate, and PBS used in the present invention has the same composition as that in the present invention, unless otherwise specified.
The umbilical cord mesenchymal stem cells are isolated and cultured by the method, and the obtained umbilical cord mesenchymal stem cells have very high survival rate and very high yield. The present methods exhibit superior technical effects in one or more aspects as described herein.
Drawings
FIG. 1: microscopic cell morphology of primary mesenchymal stem cells (100 ×).
FIG. 2: directional differentiation potential of primary cells, A) adipogenic control, B) adipogenic induction; C) osteogenic control, D) osteogenic induction; E) chondrogenic control, F) chondrogenic induction.
Detailed Description
The present invention will be further described by the following examples, however, the scope of the present invention is not limited to the following examples. It will be understood by those skilled in the art that various changes and modifications may be made to the invention without departing from the spirit and scope of the invention. The present invention has been described generally and/or specifically with respect to materials used in testing and testing methods. Although many materials and methods of operation are known in the art for the purpose of carrying out the invention, the invention is nevertheless described herein in as detail as possible.
In the present invention, the DMEM-F12 medium used in the experiments had the following formulation, unless otherwise specified: 116.6mg of anhydrous calcium chloride, 59.05mg of L-leucine, 0.042mg of linoleic acid, 0.0013mg of copper sulfate pentahydrate, 91.25mg of L-lysine hydrochloride, 0.105mg of lipoic acid, 0.05mg of ferric nitrate nonahydrate, 17.24mg of L-methionine, 8.1mg of phenol red, 0.417mg of ferrous sulfate heptahydrate, 35.48mg of L-phenylalanine, 0.081mg of 1, 4-butanediamine dihydrochloride, 311.8mg of potassium chloride, 26.25mg of L-serine, 55mg of sodium pyruvate, 28.64mg of magnesium chloride, 53.45mg of L-threonine, 0.0035mg of vitamin H, 48.84mg of anhydrous magnesium sulfate, 4.45mg of L-alanine, 2.24mg of D-calcium pantothenate, 7000mg of sodium chloride, 7.5mg of L-asparagine, 8.98mg of choline chloride, 54.35mg of anhydrous sodium dihydrogen phosphate, 6.65mg of L-aspartic acid, 2.65mg of L-cysteine, 56.52 mg of L-disodium hydrogen phosphate, 17.12 mg of L-17 mg of inositol phosphate, 6.52 mg of L-asparagine, 0.432mg of zinc sulfate heptahydrate, 7.35mg of L-glutamic acid, 2.02mg of nicotinamide, 147.5mg of L-arginine hydrochloride, 17.25mg of L-proline, 2mg of pyridoxal hydrochloride, 31.29mg of L-cystine hydrochloride, 9.02mg of L-tryptophan, 0.031mg of pyridoxine hydrochloride, 365mg of L-glutamine, 38.4mg of L-tyrosine, 0.219mg of riboflavin, 18.75mg of glycine, 52.85mg of L-valine, 2.17mg of thiamine hydrochloride, 31.48mg of L-histidine hydrochloride, 3151mg of D-glucose, 0.365mg of thymidine, 54.47mg of L-isoleucine, 2mg of hypoxanthine, 0.68mg of vitamin B12 and adding a proper amount of water to 1000 mL; preparation: dissolving the materials in 1000ml, and filtering with 0.22 μm microporous membrane for sterilization.
In the present invention, Platelet lysates used in the experiments can be readily purchased from the market, and as not specifically indicated herein, PLTGold Human Platelet Lysate from Sigma-Aldrich, having the product number SCM151, was used in the experiments.
In the present invention, collagenase type II used in the experiments can be easily obtained from the market, and as not specifically mentioned, used in the experiments herein is from Gibco.
In the present invention, bFGF (basic fibroblast growth factor) used in the experiment can be easily purchased from the market, and as not specifically mentioned, it is purchased from Sigma-Aldrich under the trade name GF003 in the experiment herein.
In the present invention, EGF (epidermal growth factor) used in the test is readily available from the market, and as not specifically mentioned herein, it is used in the test from Gibco under the reference PHG 0311L.
In the present invention, recombinant insulin used in the test can be easily obtained from the market, and as not specifically mentioned, it is used in the test herein that it is obtained from Solarbio and its product number is I8830.
In the present invention, the recombinant pancreatin solution used in the test can be easily obtained from the market, and as not specifically mentioned, the recombinant pancreatin solution of 2000u/ml concentration available from Rambox corporation, cat # RT2S01, is used in the test herein.
In the present invention, the D-Hanks solution used in the test was formulated and prepared as follows, unless otherwise specified: 8.0g NaCl, 0.4g KCl, 0.06g KH2PO4, 0.08g Na2HPO4.12H2O, 0.35g NaHCO3 and water to 1000 ml; preparation: dissolving the materials in 1000ml, and filtering with 0.22 μm microporous membrane for sterilization.
In the present invention, the primary complete medium used in the experiments was prepared with DMEM-F12 medium as a medium and contained, unless otherwise specified: 0.8% platelet lysate, 1% human serum albumin, 2. mu.g/ml recombinant insulin, 15ng/ml EGF, 25ng/ml bFGF.
In the present invention, the primary supplement medium used in the experiments was prepared with DMEM-F12 medium as a medium and contained, if not specifically stated: 0.8% platelet lysate, 1% human serum albumin, 2. mu.g/ml recombinant insulin, 15ng/ml EGF, 25ng/ml bFGF, 0.1% thioglycerol, 1% fructose.
In a specific experiment of the present invention, the prepared stem cells of a certain generation were sampled, nucleated cells, i.e., MSC cells were counted using a sysmex hemocytometer, cell viability was detected by trypan blue staining, and the samples were taken for microbial detection.
Example 1: isolation culture of primary umbilical cord mesenchymal stem cells
(1) Umbilical cords from volunteer donors transported to the laboratory via cold chain at 2-8 ℃ were processed in a biosafety cabinet (sample QA);
(2) D-Hanks are fully cleaned to remove surface bloodiness, the umbilical cord is cut into small sections with the length of 3cm by using surgical scissors, the small sections are placed in a 100mm flat dish, the umbilical cord is repeatedly extruded by using surgical forceps, residual blood clots in tissues are removed, and the umbilical cord is cleaned by using D-Hanks;
(3) cutting tissue, peeling epidermis, removing artery and vein to obtain tissue of Wharton jelly, and cutting Wharton jelly into 0.25cm2Weighing small blocks of different sizes;
(4) weighing 1.5g of the tissue block of the gordonia gum obtained in the step (3) (the inoculation amount is 1.5 g/bottle, the tissue block is precisely weighed) and inoculating the tissue block to a T225 culture bottle, adding 15ml of primary complete culture medium, fully and uniformly mixing to enable the tissue block to be uniformly spread on the bottom of the bottle, and placing the bottle in a CO2 incubator (5% CO)2At 37 ℃, saturated humidity);
(5) and (3) supplementing 10ml of primary complete culture medium to the 3 rd stage for continuous culture, supplementing 10ml of primary complete culture medium to the 5 th stage for continuous culture, completely replacing the culture solution to the 7 th stage, removing the old culture medium after the cell fusion degree reaches more than 80 percent (10-11D), cleaning the cells by using D-hanks solution, adding 5ml of recombinant pancreatin solution into each bottle for digesting the cells for 2min to make the cells fall off, adding 25ml of D-hanks solution into each bottle for dilution, centrifuging for 10min at 100Xg, and re-suspending the cell sediment by using the primary complete culture medium to obtain the primary umbilical cord mesenchymal stem cells (namely P0 generation).
The above steps (1) to (5) after inoculating the T225 flasks in step (4) with the amount of each 1.5 g/flask of the gordonia gum tissue piece (exactly converted to 1.5 g/flask from the actual inoculation amount), the number of nucleated cells obtained per flask (average of 5 repetitions) was 0.618 × 10^6(n ═ 5) (herein, this data may be referred to as cell harvest amount), and the cell viability was 95.3% (n ═ 5).
Example 1 a: isolation culture of primary umbilical cord mesenchymal stem cells
The operations and materials from step (1) to step (3) are continued in example 1;
(4) weighing 1.5g of the tissue mass of Wharton's jelly obtained in step (3) of example 1 (the inoculum size is 1.5 g/bottle, the tissue mass is precisely weighed) and inoculating to a T225 culture bottle, adding 15ml of primary supplement culture medium, mixing well to make the tissue mass spread on the bottom of the bottle uniformly, placing in a CO2 incubator (5% CO 2)2At 37 ℃, saturated humidity);
(5) and (3) supplementing 10ml of primary supplement culture medium to the 3 rd stage, continuously culturing, supplementing 10ml of primary supplement culture medium to the 5 th stage, continuously culturing, completely replacing the culture solution to the 7 th stage, removing the old culture medium after the cell fusion degree reaches more than 80 percent (10-11D), cleaning the cells by using D-hanks solution, adding 5ml of recombinant pancreatin solution into each bottle to digest the cells for 2min so as to enable the cells to fall off, adding 25ml of D-hanks solution into each bottle to dilute the cells, centrifuging the solution for 10min at 100Xg, and re-suspending the cell sediment by using the primary supplement culture medium to obtain the primary umbilical cord mesenchymal stem cells (namely P0 generation).
Example 1a after the above-described steps (1) to (5) were inoculated into T225 flasks in step (4) in an amount of 1.5 g/flask of gordonia gum tissue mass (exactly converted to 1.5 g/flask from the actual inoculum amount), the number of nucleated cells (average of 5 repetitions) obtained per flask was 3.84 × 10^6(n ═ 5) (herein, this data may be referred to as cell harvest amount), and the cell viability was 94.6% (n ═ 5).
Example 1 b: primary umbilical cord mesenchymal stem cells were obtained as in example 1a, except that no thioglycerol was added to the primary supplement medium and isolated for culture. The cell harvest of primary umbilical cord mesenchymal stem cells of example 1b was 0.642 x 10^6(n ═ 5) and the cell viability was 92.6% (n ═ 5).
Example 1 c: the procedure of example 1a was followed except that fructose was not added to the primary supplemented medium, and isolated and cultured to obtain primary umbilical cord mesenchymal stem cells. The cell harvest of primary umbilical cord mesenchymal stem cells of example 1b was 0.511 × 10^6(n ═ 5) and the cell viability was 93.1% (n ═ 5).
In this document, the embodiment 1a, the embodiment 1b and the embodiment 1c can also be referred to as an auxiliary example of the embodiment 1, while the embodiment 1 can be referred to as a main example, and they can be referred to as an example family.
Compared with the example 1, the cell viability rates of the example 1a, the example 1b and the example 1c are basically the same and are all in the range of 92-96%; however, the cell harvest was about 6.21 times that of example 1a, about 1.04 times that of example 1b, and about 0.83 times that of example 1c for example 1a for example 1 b; these unexpected findings indicate that adding a small amount of cheap thioglycerol and fructose in the primary complete culture medium can not only obtain primary stem cells with substantially equivalent cell viability rate, but also promote a significant increase in cell yield of up to 4 times, and a significant increase in cell yield with substantially unchanged production cost. However, when only thioglycerol or only fructose is added, although the cell viability rate is not changed, the cell yield is not increased, and even when only thioglycerol is additionally added, the cell yield is obviously reduced.
In terms of cell viability, the main examples 2-12 and their respective auxiliary a, b, c examples also show substantially the same results as the above example 1 and its auxiliary examples (example 1a, example 1b, example 1c), and the cell viability is in the range of 92-96%, for example, the cell viability of the primary mesenchymal stem cells obtained in example 2 and the fourth of example 2a, example 2b, example 2c is 94.7%, 93.2%, 95.3%, 92.8%, respectively.
In terms of cell harvest, the main examples 2-12 and their respective auxiliary examples a, b, c also show substantially the same trend and even result as the above-mentioned example 1 and its auxiliary examples (example 1a, example 1b, example 1c), the cell harvest of the main examples 2-12 is within (0.577-0.653) × 10^6, the cell harvest of the group a auxiliary examples is 5.83-7.06 times that of their respective main examples, the cell harvest of the group b auxiliary examples is 0.93-1.21 times that of their respective main examples, and the cell harvest of the group c auxiliary examples is 0.77-0.86 times that of their respective main examples; for example, the cell harvest yields (n ═ 5) of examples 2, 2a, 2b and 2c were 0.627 × 10^6, 3.73 × 10^6(5.95 times), 0.644 × 10^6(1.03 times) and 0.517 × 10^6(0.82 times), respectively.
The primary umbilical cord mesenchymal stem cells obtained in examples 1-12 and their respective subsidiary a, b and c of the main examples herein are tested, the cell morphology is normal, and immunophenotyping shows that each primary umbilical cord mesenchymal stem cell is positive in CD73, CD90 and CD105 (all greater than 98%, for example, the stem cell CD73 obtained in example 1 is greater than 99.5%), negative in CD19, CD11b, CD31, CD45, HLADR and CD34 (all less than 2%, for example, the stem cell CD19 obtained in example 1 is less than 0.24%).
Example 2: isolation culture of primary umbilical cord mesenchymal stem cells
(1) Umbilical cords from volunteer donors (sample QB) transported to the laboratory via the 2-8 ℃ cold chain were processed in a biosafety cabinet;
(2) D-Hanks are fully cleaned to remove surface bloodiness, the umbilical cord is cut into small sections with the length of 3cm by using surgical scissors, the small sections are placed in a 100mm flat dish, the umbilical cord is repeatedly extruded by using surgical forceps, residual blood clots in tissues are removed, and the umbilical cord is cleaned by using D-Hanks;
(3) cutting tissue, peeling epidermis, removing artery and vein to obtain tissue of Wharton jelly, and cutting Wharton jelly into 0.25cm2Weighing small blocks of different sizes;
(4) weighing 1.5g of the tissue block of the gordonia gum obtained in the step (3) (the inoculation amount is 1.5 g/bottle, the tissue block is precisely weighed) and inoculating the tissue block to a T225 culture bottle, adding 15ml of primary complete culture medium, fully and uniformly mixing to enable the tissue block to be uniformly spread on the bottom of the bottle, and placing the bottle in a CO2 incubator (5% CO)2At 37 ℃, saturated humidity);
(5) and (3) supplementing 10ml of primary complete culture medium to the 3 rd stage for continuous culture, supplementing 10ml of primary complete culture medium to the 5 th stage for continuous culture, completely replacing the culture solution to the 7 th stage, removing the old culture medium after the cell fusion degree reaches more than 80 percent (10-11D), cleaning the cells by using D-hanks solution, adding 5ml of recombinant pancreatin solution into each bottle for digesting the cells for 2min to make the cells fall off, adding 25ml of D-hanks solution into each bottle for dilution, centrifuging for 10min at 100Xg, and re-suspending the cell sediment by using the primary complete culture medium to obtain the primary umbilical cord mesenchymal stem cells (namely P0 generation).
Example 2 a: isolation culture of primary umbilical cord mesenchymal stem cells
The operations and materials from step (1) to step (3) were continued in example 2;
(4) weighing 1.5g of the tissue mass of Wharton's jelly obtained in step (3) of example 2 (the inoculum size is 1.5 g/bottle, the tissue mass is precisely weighed) and inoculating to a T225 culture bottle, adding 15ml of primary supplement culture medium, mixing well to make the tissue mass spread evenly on the bottom of the bottle, placing in a CO2 incubator (5% CO 2)2At 37 ℃, saturated humidity);
(5) and (3) supplementing 10ml of primary supplement culture medium to the 3 rd stage, continuously culturing, supplementing 10ml of primary supplement culture medium to the 5 th stage, continuously culturing, completely replacing the culture solution to the 7 th stage, removing the old culture medium after the cell fusion degree reaches more than 80 percent (10-11D), cleaning the cells by using D-hanks solution, adding 5ml of recombinant pancreatin solution into each bottle to digest the cells for 2min so as to enable the cells to fall off, adding 25ml of D-hanks solution into each bottle to dilute the cells, centrifuging the solution for 10min at 100Xg, and re-suspending the cell sediment by using the primary supplement culture medium to obtain the primary umbilical cord mesenchymal stem cells (namely P0 generation).
Example 2 b: primary umbilical cord mesenchymal stem cells were obtained as in example 2a, except that no thioglycerol was added to the primary supplement medium and isolated for culture.
Example 2 c: the procedure of example 2a was followed except that fructose was not added to the primary supplemented medium, and isolated and cultured to obtain primary umbilical cord mesenchymal stem cells.
Example 3: isolation culture of primary umbilical cord mesenchymal stem cells
(1) Umbilical cords from volunteer donors transported to the laboratory via the 2-8 ℃ cold chain (sample QC) were processed in a biosafety cabinet;
(2) D-Hanks are fully cleaned to remove surface bloodiness, the umbilical cord is cut into small sections with the length of 3cm by using surgical scissors, the small sections are placed in a 100mm flat dish, the umbilical cord is repeatedly extruded by using surgical forceps, residual blood clots in tissues are removed, and the umbilical cord is cleaned by using D-Hanks;
(3) cutting tissue, peeling epidermis, removing artery and vein to obtain tissue of Wharton jelly, and cutting Wharton jelly into 0.25cm2Weighing small blocks of different sizes;
(4) weighing 1.5g of the tissue block of the gordonia gum obtained in the step (3) (the inoculation amount is 1.5 g/bottle, the tissue block is precisely weighed) and inoculating the tissue block to a T225 culture bottle, adding 15ml of primary complete culture medium, fully and uniformly mixing to enable the tissue block to be uniformly spread on the bottom of the bottle, and placing the bottle in a CO2 incubator (5% CO)2At 37 ℃, saturated humidity);
(5) and (3) supplementing 10ml of primary complete culture medium to the 3 rd stage for continuous culture, supplementing 10ml of primary complete culture medium to the 5 th stage for continuous culture, completely replacing the culture solution to the 7 th stage, removing the old culture medium after the cell fusion degree reaches more than 80 percent (10-11D), cleaning the cells by using D-hanks solution, adding 5ml of recombinant pancreatin solution into each bottle for digesting the cells for 2min to make the cells fall off, adding 25ml of D-hanks solution into each bottle for dilution, centrifuging for 10min at 100Xg, and re-suspending the cell sediment by using the primary complete culture medium to obtain the primary umbilical cord mesenchymal stem cells (namely P0 generation).
Example 3 a: isolation culture of primary umbilical cord mesenchymal stem cells
The operations and materials from step (1) to step (3) are continued in example 3;
(4) weighing 1.5g of the tissue mass of Wharton's jelly obtained in step (3) of example 3 (the inoculum size is 1.5 g/bottle, the tissue mass is precisely weighed) and inoculating to a T225 culture bottle, adding 15ml of primary supplement culture medium, mixing well to make the tissue mass spread evenly on the bottom of the bottle, placing in a CO2 incubator (5% CO 2)2At 37 ℃, saturated humidity);
(5) and (3) supplementing 10ml of primary supplement culture medium to the 3 rd stage, continuously culturing, supplementing 10ml of primary supplement culture medium to the 5 th stage, continuously culturing, completely replacing the culture solution to the 7 th stage, removing the old culture medium after the cell fusion degree reaches more than 80 percent (10-11D), cleaning the cells by using D-hanks solution, adding 5ml of recombinant pancreatin solution into each bottle to digest the cells for 2min so as to enable the cells to fall off, adding 25ml of D-hanks solution into each bottle to dilute the cells, centrifuging the solution for 10min at 100Xg, and re-suspending the cell sediment by using the primary supplement culture medium to obtain the primary umbilical cord mesenchymal stem cells (namely P0 generation).
Example 3 b: primary umbilical cord mesenchymal stem cells were obtained as in example 3a, except that no thioglycerol was added to the primary supplement medium and isolated for culture.
Example 3 c: the procedure of example 3a was followed except that fructose was not added to the primary supplemented medium, and isolated and cultured to obtain primary umbilical cord mesenchymal stem cells.
Example 4: isolation culture of primary umbilical cord mesenchymal stem cells
(1) Umbilical cords from volunteer donors transported to the laboratory via the cold chain at 2-8 ℃ were processed in biosafety cabinets (sample QD);
(2) D-Hanks are fully cleaned to remove surface bloodiness, the umbilical cord is cut into small sections with the length of 3cm by using surgical scissors, the small sections are placed in a 100mm flat dish, the umbilical cord is repeatedly extruded by using surgical forceps, residual blood clots in tissues are removed, and the umbilical cord is cleaned by using D-Hanks;
(3) cutting tissue, peeling epidermis, removing artery and vein to obtain tissue of Wharton jelly, and cutting Wharton jelly into 0.25cm2Weighing small blocks of different sizes;
(4) weighing 1.5g of the tissue block of the gordonia gum obtained in the step (3) (the inoculation amount is 1.5 g/bottle, the tissue block is precisely weighed) and inoculating the tissue block to a T225 culture bottle, adding 15ml of primary complete culture medium, fully and uniformly mixing to enable the tissue block to be uniformly spread on the bottom of the bottle, and placing the bottle in a CO2 incubator (5% CO)2At 37 ℃, saturated humidity);
(5) and (3) supplementing 10ml of primary complete culture medium to the 3 rd stage for continuous culture, supplementing 10ml of primary complete culture medium to the 5 th stage for continuous culture, completely replacing the culture solution to the 7 th stage, removing the old culture medium after the cell fusion degree reaches more than 80 percent (10-11D), cleaning the cells by using D-hanks solution, adding 5ml of recombinant pancreatin solution into each bottle for digesting the cells for 2min to make the cells fall off, adding 25ml of D-hanks solution into each bottle for dilution, centrifuging for 10min at 100Xg, and re-suspending the cell sediment by using the primary complete culture medium to obtain the primary umbilical cord mesenchymal stem cells (namely P0 generation).
Example 4 a: isolation culture of Primary umbilical cord mesenchymeStem cells
The operations and materials from step (1) to step (3) were continued in example 4;
(4) weighing 1.5g of the tissue mass of Wharton's jelly obtained in step (3) of example 4 (the inoculum size is 1.5 g/bottle, the tissue mass is precisely weighed) and inoculating to a T225 culture bottle, adding 15ml of primary supplement culture medium, mixing well to make the tissue mass spread evenly on the bottom of the bottle, placing in a CO2 incubator (5% CO 2)2At 37 ℃, saturated humidity);
(5) and (3) supplementing 10ml of primary supplement culture medium to the 3 rd stage, continuously culturing, supplementing 10ml of primary supplement culture medium to the 5 th stage, continuously culturing, completely replacing the culture solution to the 7 th stage, removing the old culture medium after the cell fusion degree reaches more than 80 percent (10-11D), cleaning the cells by using D-hanks solution, adding 5ml of recombinant pancreatin solution into each bottle to digest the cells for 2min so as to enable the cells to fall off, adding 25ml of D-hanks solution into each bottle to dilute the cells, centrifuging the solution for 10min at 100Xg, and re-suspending the cell sediment by using the primary supplement culture medium to obtain the primary umbilical cord mesenchymal stem cells (namely P0 generation).
Example 4 b: the procedure of example 4a was followed except that thioglycerol was not added to the primary supplement medium and isolated for culture to obtain primary umbilical cord mesenchymal stem cells.
Example 4 c: the procedure of example 4a was followed except that fructose was not added to the primary supplemented medium, and isolated and cultured to obtain primary umbilical cord mesenchymal stem cells.
Example 5: isolation culture of primary umbilical cord mesenchymal stem cells
(1) Umbilical cords (sample QE) from volunteer donors transported to the laboratory via the cold chain at 2-8 ℃ were processed in a biosafety cabinet;
(2) D-Hanks are fully cleaned to remove surface bloodiness, the umbilical cord is cut into small sections with the length of 3cm by using surgical scissors, the small sections are placed in a 100mm flat dish, the umbilical cord is repeatedly extruded by using surgical forceps, residual blood clots in tissues are removed, and the umbilical cord is cleaned by using D-Hanks;
(3) cutting tissue, peeling epidermis, removing artery and vein to obtain tissue of Wharton jelly, and cutting Wharton jelly into 0.25cm2Weighing small blocks of different sizes;
(4) weighing the product obtained in the step (3)Inoculating 1.5g of Wharton's jelly tissue block (inoculum size 1.5 g/bottle, precisely weighing tissue block) to T225 culture bottle, adding 15ml of primary complete culture medium, mixing, spreading the tissue block at the bottom of the bottle, and placing in CO2 incubator (5% CO)2At 37 ℃, saturated humidity);
(5) and (3) supplementing 10ml of primary complete culture medium to the 3 rd stage for continuous culture, supplementing 10ml of primary complete culture medium to the 5 th stage for continuous culture, completely replacing the culture solution to the 7 th stage, removing the old culture medium after the cell fusion degree reaches more than 80 percent (10-11D), cleaning the cells by using D-hanks solution, adding 5ml of recombinant pancreatin solution into each bottle for digesting the cells for 2min to make the cells fall off, adding 25ml of D-hanks solution into each bottle for dilution, centrifuging for 10min at 100Xg, and re-suspending the cell sediment by using the primary complete culture medium to obtain the primary umbilical cord mesenchymal stem cells (namely P0 generation).
Example 5 a: isolation culture of primary umbilical cord mesenchymal stem cells
The operations and materials from step (1) to step (3) were continued in example 5;
(4) weighing 1.5g of the tissue mass of Wharton's jelly obtained in step (3) of example 5 (the inoculum size is 1.5 g/bottle, the tissue mass is precisely weighed) and inoculating to a T225 culture bottle, adding 15ml of primary supplement culture medium, mixing well to make the tissue mass spread evenly on the bottom of the bottle, placing in a CO2 incubator (5% CO 2)2At 37 ℃, saturated humidity);
(5) and (3) supplementing 10ml of primary supplement culture medium to the 3 rd stage, continuously culturing, supplementing 10ml of primary supplement culture medium to the 5 th stage, continuously culturing, completely replacing the culture solution to the 7 th stage, removing the old culture medium after the cell fusion degree reaches more than 80 percent (10-11D), cleaning the cells by using D-hanks solution, adding 5ml of recombinant pancreatin solution into each bottle to digest the cells for 2min so as to enable the cells to fall off, adding 25ml of D-hanks solution into each bottle to dilute the cells, centrifuging the solution for 10min at 100Xg, and re-suspending the cell sediment by using the primary supplement culture medium to obtain the primary umbilical cord mesenchymal stem cells (namely P0 generation).
Example 5 b: primary umbilical cord mesenchymal stem cells were obtained as in example 5a, except that no thioglycerol was added to the primary supplement medium and isolated for culture.
Example 5 c: the procedure of example 5a was followed except that fructose was not added to the primary supplemented medium, and isolated and cultured to obtain primary umbilical cord mesenchymal stem cells.
Example 6: isolation culture of primary umbilical cord mesenchymal stem cells
(1) Umbilical cords from volunteer donors transported to the laboratory via the cold chain at 2-8 ℃ were processed in a biosafety cabinet (sample QF);
(2) D-Hanks are fully cleaned to remove surface bloodiness, the umbilical cord is cut into small sections with the length of 3cm by using surgical scissors, the small sections are placed in a 100mm flat dish, the umbilical cord is repeatedly extruded by using surgical forceps, residual blood clots in tissues are removed, and the umbilical cord is cleaned by using D-Hanks;
(3) cutting tissue, peeling epidermis, removing artery and vein to obtain tissue of Wharton jelly, and cutting Wharton jelly into 0.25cm2Weighing small blocks of different sizes;
(4) weighing 1.5g of the tissue block of the gordonia gum obtained in the step (3) (the inoculation amount is 1.5 g/bottle, the tissue block is precisely weighed) and inoculating the tissue block to a T225 culture bottle, adding 15ml of primary complete culture medium, fully and uniformly mixing to enable the tissue block to be uniformly spread on the bottom of the bottle, and placing the bottle in a CO2 incubator (5% CO)2At 37 ℃, saturated humidity);
(5) and (3) supplementing 10ml of primary complete culture medium to the 3 rd stage for continuous culture, supplementing 10ml of primary complete culture medium to the 5 th stage for continuous culture, completely replacing the culture solution to the 7 th stage, removing the old culture medium after the cell fusion degree reaches more than 80 percent (10-11D), cleaning the cells by using D-hanks solution, adding 5ml of recombinant pancreatin solution into each bottle for digesting the cells for 2min to make the cells fall off, adding 25ml of D-hanks solution into each bottle for dilution, centrifuging for 10min at 100Xg, and re-suspending the cell sediment by using the primary complete culture medium to obtain the primary umbilical cord mesenchymal stem cells (namely P0 generation).
Example 6 a: isolation culture of primary umbilical cord mesenchymal stem cells
The operations and materials from step (1) to step (3) were continued in example 6;
(4) weighing 1.5g of the tissue mass of Wharton's jelly obtained in step (3) of example 6 (the inoculum size is 1.5 g/bottle, the tissue mass is precisely weighed) and inoculating to a T225 culture bottle, adding 15ml of primary supplement culture medium, mixing well to make the tissue mass evenly spread on the bottom of the bottle, placing CO2 for cultureRaising box (5% CO)2At 37 ℃, saturated humidity);
(5) and (3) supplementing 10ml of primary supplement culture medium to the 3 rd stage, continuously culturing, supplementing 10ml of primary supplement culture medium to the 5 th stage, continuously culturing, completely replacing the culture solution to the 7 th stage, removing the old culture medium after the cell fusion degree reaches more than 80 percent (10-11D), cleaning the cells by using D-hanks solution, adding 5ml of recombinant pancreatin solution into each bottle to digest the cells for 2min so as to enable the cells to fall off, adding 25ml of D-hanks solution into each bottle to dilute the cells, centrifuging the solution for 10min at 100Xg, and re-suspending the cell sediment by using the primary supplement culture medium to obtain the primary umbilical cord mesenchymal stem cells (namely P0 generation).
Example 6 b: primary umbilical cord mesenchymal stem cells were obtained as in example 6a, except that no thioglycerol was added to the primary supplement medium and isolated for culture.
Example 6 c: the procedure of example 6a was followed except that fructose was not added to the primary supplemented medium, and isolated and cultured to obtain primary umbilical cord mesenchymal stem cells.
Example 7: isolation culture of primary umbilical cord mesenchymal stem cells
(1) Umbilical cords from volunteer donors transported to the laboratory via the cold chain at 2-8 ℃ were processed in biosafety cabinets (sample QG);
(2) D-Hanks are fully cleaned to remove surface bloodiness, the umbilical cord is cut into small sections with the length of 3cm by using surgical scissors, the small sections are placed in a 100mm flat dish, the umbilical cord is repeatedly extruded by using surgical forceps, residual blood clots in tissues are removed, and the umbilical cord is cleaned by using D-Hanks;
(3) cutting tissue, peeling epidermis, removing artery and vein to obtain tissue of Wharton jelly, and cutting Wharton jelly into 0.25cm2Weighing small blocks of different sizes;
(4) weighing 1.5g of the tissue block of the gordonia gum obtained in the step (3) (the inoculation amount is 1.5 g/bottle, the tissue block is precisely weighed) and inoculating the tissue block to a T225 culture bottle, adding 15ml of primary complete culture medium, fully and uniformly mixing to enable the tissue block to be uniformly spread on the bottom of the bottle, and placing the bottle in a CO2 incubator (5% CO)2At 37 ℃, saturated humidity);
(5) and (3) supplementing 10ml of primary complete culture medium to the 3 rd stage for continuous culture, supplementing 10ml of primary complete culture medium to the 5 th stage for continuous culture, completely replacing the culture solution to the 7 th stage, removing the old culture medium after the cell fusion degree reaches more than 80 percent (10-11D), cleaning the cells by using D-hanks solution, adding 5ml of recombinant pancreatin solution into each bottle for digesting the cells for 2min to make the cells fall off, adding 25ml of D-hanks solution into each bottle for dilution, centrifuging for 10min at 100Xg, and re-suspending the cell sediment by using the primary complete culture medium to obtain the primary umbilical cord mesenchymal stem cells (namely P0 generation).
Example 7 a: isolation culture of primary umbilical cord mesenchymal stem cells
The operations and materials from step (1) to step (3) were continued in example 7;
(4) weighing 1.5g of the tissue mass of Wharton's jelly obtained in step (3) of example 7 (the inoculum size is 1.5 g/bottle, the tissue mass is precisely weighed) and inoculating to a T225 culture bottle, adding 15ml of primary supplement culture medium, mixing well to make the tissue mass spread evenly on the bottom of the bottle, placing in a CO2 incubator (5% CO 2)2At 37 ℃, saturated humidity);
(5) and (3) supplementing 10ml of primary supplement culture medium to the 3 rd stage, continuously culturing, supplementing 10ml of primary supplement culture medium to the 5 th stage, continuously culturing, completely replacing the culture solution to the 7 th stage, removing the old culture medium after the cell fusion degree reaches more than 80 percent (10-11D), cleaning the cells by using D-hanks solution, adding 5ml of recombinant pancreatin solution into each bottle to digest the cells for 2min so as to enable the cells to fall off, adding 25ml of D-hanks solution into each bottle to dilute the cells, centrifuging the solution for 10min at 100Xg, and re-suspending the cell sediment by using the primary supplement culture medium to obtain the primary umbilical cord mesenchymal stem cells (namely P0 generation).
Example 7 b: primary umbilical cord mesenchymal stem cells were obtained as in example 7a, except that no thioglycerol was added to the primary supplement medium and isolated for culture.
Example 7 c: the procedure of example 7a was followed except that fructose was not added to the primary supplemented medium, and isolated and cultured to obtain primary umbilical cord mesenchymal stem cells.
Example 8: isolation culture of primary umbilical cord mesenchymal stem cells
(1) Umbilical cords from volunteer donors transported to the laboratory via the cold chain at 2-8 ℃ were processed in biosafety cabinets (sample QH);
(2) D-Hanks are fully cleaned to remove surface bloodiness, the umbilical cord is cut into small sections with the length of 3cm by using surgical scissors, the small sections are placed in a 100mm flat dish, the umbilical cord is repeatedly extruded by using surgical forceps, residual blood clots in tissues are removed, and the umbilical cord is cleaned by using D-Hanks;
(3) cutting tissue, peeling epidermis, removing artery and vein to obtain tissue of Wharton jelly, and cutting Wharton jelly into 0.25cm2Weighing small blocks of different sizes;
(4) weighing 1.5g of the tissue block of the gordonia gum obtained in the step (3) (the inoculation amount is 1.5 g/bottle, the tissue block is precisely weighed) and inoculating the tissue block to a T225 culture bottle, adding 15ml of primary complete culture medium, fully and uniformly mixing to enable the tissue block to be uniformly spread on the bottom of the bottle, and placing the bottle in a CO2 incubator (5% CO)2At 37 ℃, saturated humidity);
(5) and (3) supplementing 10ml of primary complete culture medium to the 3 rd stage for continuous culture, supplementing 10ml of primary complete culture medium to the 5 th stage for continuous culture, completely replacing the culture solution to the 7 th stage, removing the old culture medium after the cell fusion degree reaches more than 80 percent (10-11D), cleaning the cells by using D-hanks solution, adding 5ml of recombinant pancreatin solution into each bottle for digesting the cells for 2min to make the cells fall off, adding 25ml of D-hanks solution into each bottle for dilution, centrifuging for 10min at 100Xg, and re-suspending the cell sediment by using the primary complete culture medium to obtain the primary umbilical cord mesenchymal stem cells (namely P0 generation).
Example 8 a: isolation culture of primary umbilical cord mesenchymal stem cells
The operations and materials from step (1) to step (3) were continued in example 8;
(4) weighing 1.5g of the tissue mass of Wharton's jelly obtained in step (3) of example 8 (the inoculum size is 1.5 g/bottle, the tissue mass is precisely weighed) and inoculating to a T225 culture bottle, adding 15ml of primary supplement culture medium, mixing well to make the tissue mass spread evenly on the bottom of the bottle, placing in a CO2 incubator (5% CO 2)2At 37 ℃, saturated humidity);
(5) and (3) supplementing 10ml of primary supplement culture medium to the 3 rd stage, continuously culturing, supplementing 10ml of primary supplement culture medium to the 5 th stage, continuously culturing, completely replacing the culture solution to the 7 th stage, removing the old culture medium after the cell fusion degree reaches more than 80 percent (10-11D), cleaning the cells by using D-hanks solution, adding 5ml of recombinant pancreatin solution into each bottle to digest the cells for 2min so as to enable the cells to fall off, adding 25ml of D-hanks solution into each bottle to dilute the cells, centrifuging the solution for 10min at 100Xg, and re-suspending the cell sediment by using the primary supplement culture medium to obtain the primary umbilical cord mesenchymal stem cells (namely P0 generation).
Example 8 b: the procedure of example 8a was followed except that thioglycerol was not added to the primary supplement medium and isolated for culture to obtain primary umbilical cord mesenchymal stem cells.
Example 8 c: the procedure of example 8a was followed except that fructose was not added to the primary supplemented medium, and isolated and cultured to obtain primary umbilical cord mesenchymal stem cells.
Example 9: isolation culture of primary umbilical cord mesenchymal stem cells
(1) Umbilical cords from volunteer donors transported to the laboratory via the cold chain at 2-8 ℃ were processed in a biosafety cabinet (sample QI);
(2) D-Hanks are fully cleaned to remove surface bloodiness, the umbilical cord is cut into small sections with the length of 3cm by using surgical scissors, the small sections are placed in a 100mm flat dish, the umbilical cord is repeatedly extruded by using surgical forceps, residual blood clots in tissues are removed, and the umbilical cord is cleaned by using D-Hanks;
(3) cutting tissue, peeling epidermis, removing artery and vein to obtain tissue of Wharton jelly, and cutting Wharton jelly into 0.25cm2Weighing small blocks of different sizes;
(4) weighing 1.5g of the tissue block of the gordonia gum obtained in the step (3) (the inoculation amount is 1.5 g/bottle, the tissue block is precisely weighed) and inoculating the tissue block to a T225 culture bottle, adding 15ml of primary complete culture medium, fully and uniformly mixing to enable the tissue block to be uniformly spread on the bottom of the bottle, and placing the bottle in a CO2 incubator (5% CO)2At 37 ℃, saturated humidity);
(5) and (3) supplementing 10ml of primary complete culture medium to the 3 rd stage for continuous culture, supplementing 10ml of primary complete culture medium to the 5 th stage for continuous culture, completely replacing the culture solution to the 7 th stage, removing the old culture medium after the cell fusion degree reaches more than 80 percent (10-11D), cleaning the cells by using D-hanks solution, adding 5ml of recombinant pancreatin solution into each bottle for digesting the cells for 2min to make the cells fall off, adding 25ml of D-hanks solution into each bottle for dilution, centrifuging for 10min at 100Xg, and re-suspending the cell sediment by using the primary complete culture medium to obtain the primary umbilical cord mesenchymal stem cells (namely P0 generation).
Example 9 a: isolation culture of primary umbilical cord mesenchymal stem cells
The operations and materials from step (1) to step (3) were continued from example 9;
(4) weighing 1.5g of the tissue mass of Wharton's jelly obtained in step (3) of example 9 (the inoculum size is 1.5 g/bottle, the tissue mass is precisely weighed) and inoculating to a T225 culture bottle, adding 15ml of primary supplement culture medium, mixing well to make the tissue mass spread evenly on the bottom of the bottle, placing in a CO2 incubator (5% CO 2)2At 37 ℃, saturated humidity);
(5) and (3) supplementing 10ml of primary supplement culture medium to the 3 rd stage, continuously culturing, supplementing 10ml of primary supplement culture medium to the 5 th stage, continuously culturing, completely replacing the culture solution to the 7 th stage, removing the old culture medium after the cell fusion degree reaches more than 80 percent (10-11D), cleaning the cells by using D-hanks solution, adding 5ml of recombinant pancreatin solution into each bottle to digest the cells for 2min so as to enable the cells to fall off, adding 25ml of D-hanks solution into each bottle to dilute the cells, centrifuging the solution for 10min at 100Xg, and re-suspending the cell sediment by using the primary supplement culture medium to obtain the primary umbilical cord mesenchymal stem cells (namely P0 generation).
Example 9 b: primary umbilical cord mesenchymal stem cells were obtained as in example 9a, except that no thioglycerol was added to the primary supplement medium and isolated for culture.
Example 9 c: the procedure of example 9a was followed except that fructose was not added to the primary supplemented medium, and isolated and cultured to obtain primary umbilical cord mesenchymal stem cells.
Example 10: isolation culture of primary umbilical cord mesenchymal stem cells
(1) Umbilical cords from volunteer donors transported to the laboratory via the cold chain at 2-8 ℃ were processed in biosafety cabinets (sample QJ);
(2) D-Hanks are fully cleaned to remove surface bloodiness, the umbilical cord is cut into small sections with the length of 3cm by using surgical scissors, the small sections are placed in a 100mm flat dish, the umbilical cord is repeatedly extruded by using surgical forceps, residual blood clots in tissues are removed, and the umbilical cord is cleaned by using D-Hanks;
(3) cutting tissue, peeling epidermis, removing artery and vein to obtain tissue of Wharton jelly, and cutting Wharton jelly into 0.25cm2Weighing small blocks of different sizes;
(4) weighing 1.5g of the tissue block of the gordonia gum obtained in the step (3) (the inoculation amount is 1.5 g/bottle, the tissue block is precisely weighed) and inoculating the tissue block to a T225 culture bottle, adding 15ml of primary complete culture medium, fully and uniformly mixing to enable the tissue block to be uniformly spread on the bottom of the bottle, and placing the bottle in a CO2 incubator (5% CO)2At 37 ℃, saturated humidity);
(5) and (3) supplementing 10ml of primary complete culture medium to the 3 rd stage for continuous culture, supplementing 10ml of primary complete culture medium to the 5 th stage for continuous culture, completely replacing the culture solution to the 7 th stage, removing the old culture medium after the cell fusion degree reaches more than 80 percent (10-11D), cleaning the cells by using D-hanks solution, adding 5ml of recombinant pancreatin solution into each bottle for digesting the cells for 2min to make the cells fall off, adding 25ml of D-hanks solution into each bottle for dilution, centrifuging for 10min at 100Xg, and re-suspending the cell sediment by using the primary complete culture medium to obtain the primary umbilical cord mesenchymal stem cells (namely P0 generation).
Example 10 a: isolation culture of primary umbilical cord mesenchymal stem cells
The operations and materials from step (1) to step (3) were continued in example 10;
(4) weighing 1.5g of the tissue mass of Wharton's jelly obtained in step (3) of example 10 (the inoculum size is 1.5 g/bottle, the tissue mass is precisely weighed) and inoculating to a T225 culture bottle, adding 15ml of primary supplement culture medium, mixing well to make the tissue mass spread evenly on the bottom of the bottle, placing in a CO2 incubator (5% CO 2)2At 37 ℃, saturated humidity);
(5) and (3) supplementing 10ml of primary supplement culture medium to the 3 rd stage, continuously culturing, supplementing 10ml of primary supplement culture medium to the 5 th stage, continuously culturing, completely replacing the culture solution to the 7 th stage, removing the old culture medium after the cell fusion degree reaches more than 80 percent (10-11D), cleaning the cells by using D-hanks solution, adding 5ml of recombinant pancreatin solution into each bottle to digest the cells for 2min so as to enable the cells to fall off, adding 25ml of D-hanks solution into each bottle to dilute the cells, centrifuging the solution for 10min at 100Xg, and re-suspending the cell sediment by using the primary supplement culture medium to obtain the primary umbilical cord mesenchymal stem cells (namely P0 generation).
Example 10 b: primary umbilical cord mesenchymal stem cells were obtained as in example 10a, except that no thioglycerol was added to the primary supplement medium and isolated for culture.
Example 10 c: the procedure of example 10a was followed except that fructose was not added to the primary supplemented medium, and isolated and cultured to obtain primary umbilical cord mesenchymal stem cells.
Example 11: isolation culture of primary umbilical cord mesenchymal stem cells
(1) Umbilical cords from volunteer donors (sample QK) transported to the laboratory via the cold chain at 2-8 ℃ were processed in a biosafety cabinet;
(2) D-Hanks are fully cleaned to remove surface bloodiness, the umbilical cord is cut into small sections with the length of 3cm by using surgical scissors, the small sections are placed in a 100mm flat dish, the umbilical cord is repeatedly extruded by using surgical forceps, residual blood clots in tissues are removed, and the umbilical cord is cleaned by using D-Hanks;
(3) cutting tissue, peeling epidermis, removing artery and vein to obtain tissue of Wharton jelly, and cutting Wharton jelly into 0.25cm2Weighing small blocks of different sizes;
(4) weighing 1.5g of the tissue block of the gordonia gum obtained in the step (3) (the inoculation amount is 1.5 g/bottle, the tissue block is precisely weighed) and inoculating the tissue block to a T225 culture bottle, adding 15ml of primary complete culture medium, fully and uniformly mixing to enable the tissue block to be uniformly spread on the bottom of the bottle, and placing the bottle in a CO2 incubator (5% CO)2At 37 ℃, saturated humidity);
(5) and (3) supplementing 10ml of primary complete culture medium to the 3 rd stage for continuous culture, supplementing 10ml of primary complete culture medium to the 5 th stage for continuous culture, completely replacing the culture solution to the 7 th stage, removing the old culture medium after the cell fusion degree reaches more than 80 percent (10-11D), cleaning the cells by using D-hanks solution, adding 5ml of recombinant pancreatin solution into each bottle for digesting the cells for 2min to make the cells fall off, adding 25ml of D-hanks solution into each bottle for dilution, centrifuging for 10min at 100Xg, and re-suspending the cell sediment by using the primary complete culture medium to obtain the primary umbilical cord mesenchymal stem cells (namely P0 generation).
Example 11 a: isolation culture of primary umbilical cord mesenchymal stem cells
The operations and materials of the steps (1) to (3) are continued from the example 11;
(4) 1.5g of the tissue piece of Wharton's jelly obtained in step (3) of example 11 (the amount of inoculation was 1.5 g/bottle, the tissue piece was precisely weighed) was weighed and inoculated into a T225 flask, and 15ml of primary culture medium was addedSupplementing culture medium, mixing to make tissue blocks uniformly spread on the bottom of the bottle, placing in CO2 incubator (5% CO)2At 37 ℃, saturated humidity);
(5) and (3) supplementing 10ml of primary supplement culture medium to the 3 rd stage, continuously culturing, supplementing 10ml of primary supplement culture medium to the 5 th stage, continuously culturing, completely replacing the culture solution to the 7 th stage, removing the old culture medium after the cell fusion degree reaches more than 80 percent (10-11D), cleaning the cells by using D-hanks solution, adding 5ml of recombinant pancreatin solution into each bottle to digest the cells for 2min so as to enable the cells to fall off, adding 25ml of D-hanks solution into each bottle to dilute the cells, centrifuging the solution for 10min at 100Xg, and re-suspending the cell sediment by using the primary supplement culture medium to obtain the primary umbilical cord mesenchymal stem cells (namely P0 generation).
Example 11 b: primary umbilical cord mesenchymal stem cells were obtained as in example 11a, except that no thioglycerol was added to the primary supplement medium and isolated for culture.
Example 11 c: the procedure of example 11a was followed except that fructose was not added to the primary supplemented medium, and isolated and cultured to obtain primary umbilical cord mesenchymal stem cells.
Example 12: isolation culture of primary umbilical cord mesenchymal stem cells
(1) Umbilical cords from volunteer donors transported to the laboratory via the cold chain at 2-8 ℃ were processed in biosafety cabinets (sample QL);
(2) D-Hanks are fully cleaned to remove surface bloodiness, the umbilical cord is cut into small sections with the length of 3cm by using surgical scissors, the small sections are placed in a 100mm flat dish, the umbilical cord is repeatedly extruded by using surgical forceps, residual blood clots in tissues are removed, and the umbilical cord is cleaned by using D-Hanks;
(3) cutting tissue, peeling epidermis, removing artery and vein to obtain tissue of Wharton jelly, and cutting Wharton jelly into 0.25cm2Weighing small blocks of different sizes;
(4) weighing 1.5g of the tissue block of the gordonia gum obtained in the step (3) (the inoculation amount is 1.5 g/bottle, the tissue block is precisely weighed) and inoculating the tissue block to a T225 culture bottle, adding 15ml of primary complete culture medium, fully and uniformly mixing to enable the tissue block to be uniformly spread on the bottom of the bottle, and placing the bottle in a CO2 incubator (5% CO)2At 37 ℃, saturated humidity);
(5) and (3) supplementing 10ml of primary complete culture medium to the 3 rd stage for continuous culture, supplementing 10ml of primary complete culture medium to the 5 th stage for continuous culture, completely replacing the culture solution to the 7 th stage, removing the old culture medium after the cell fusion degree reaches more than 80 percent (10-11D), cleaning the cells by using D-hanks solution, adding 5ml of recombinant pancreatin solution into each bottle for digesting the cells for 2min to make the cells fall off, adding 25ml of D-hanks solution into each bottle for dilution, centrifuging for 10min at 100Xg, and re-suspending the cell sediment by using the primary complete culture medium to obtain the primary umbilical cord mesenchymal stem cells (namely P0 generation).
Example 12 a: isolation culture of primary umbilical cord mesenchymal stem cells
The operations and materials from step (1) to step (3) were continued from example 12;
(4) weighing 1.5g of the tissue mass of Wharton's jelly obtained in step (3) of example 12 (the inoculum size is 1.5 g/bottle, the tissue mass is precisely weighed) and inoculating to a T225 culture bottle, adding 15ml of primary supplement culture medium, mixing well to make the tissue mass spread evenly on the bottom of the bottle, placing in a CO2 incubator (5% CO 2)2At 37 ℃, saturated humidity);
(5) and (3) supplementing 10ml of primary supplement culture medium to the 3 rd stage, continuously culturing, supplementing 10ml of primary supplement culture medium to the 5 th stage, continuously culturing, completely replacing the culture solution to the 7 th stage, removing the old culture medium after the cell fusion degree reaches more than 80 percent (10-11D), cleaning the cells by using D-hanks solution, adding 5ml of recombinant pancreatin solution into each bottle to digest the cells for 2min so as to enable the cells to fall off, adding 25ml of D-hanks solution into each bottle to dilute the cells, centrifuging the solution for 10min at 100Xg, and re-suspending the cell sediment by using the primary supplement culture medium to obtain the primary umbilical cord mesenchymal stem cells (namely P0 generation).
Example 12 b: primary umbilical cord mesenchymal stem cells were obtained as in example 12a, except that no thioglycerol was added to the primary supplement medium and isolated for culture.
Example 12 c: the procedure of example 12a was followed except that fructose was not added to the primary supplemented medium, and isolated and cultured to obtain primary umbilical cord mesenchymal stem cells.
The complete subculture medium used in the following examples 21 to 28 was prepared using a DMEM-F12 medium as a medium and contained: 2% platelet lysate, 1% human serum albumin, 2. mu.g/ml recombinant insulin, 10ng/ml EGF, 15ng/ml bFGF, 0.035% thioglycerol, 1% fructose.
Example 21: subculture of umbilical cord mesenchymal stem cells
Subculture was performed with the umbilical cord mesenchymal stem cells P0 generation obtained in example 1a, as follows:
(b1) inoculating primary (namely P0 generation) mesenchymal stem cells into a T225 bottle according to the density of 5000/cm2, supplementing a passage complete culture medium to 45ml, placing the bottle in a CO2 incubator (5% CO2, 37 ℃, saturation humidity) to culture until the cell fusion degree reaches 70-80% (generally reaching on the 3 rd day), abandoning the old culture medium, cleaning the cells by using a D-hanks solution, adding 5ml of a recombinant pancreatin solution into each bottle for digesting the cells for 2min to ensure that the cells fall off, adding 15ml of the D-hanks solution into each bottle for diluting, combining all cell suspensions into a 50ml centrifugal tube, centrifuging, precipitating the cells by using the passage complete culture medium to obtain the P1 generation mesenchymal stem cells, and then sampling to perform cell counting and activity rate measurement;
(b2) inoculating the mesenchymal stem cells of the P1 generation into a T225 bottle according to the density of 5000/cm2, supplementing a complete subculture medium to 45ml, putting the bottle in a CO2 incubator (5% CO2, 37 ℃, and saturation humidity), and carrying out subculture according to a P1 subculture method to obtain the mesenchymal stem cells of the P2 generation; then, the cells are continuously passaged to the P10 generation by the method of the above P1 generation and P2 generation, and mesenchymal stem cells of each generation are obtained.
Example 22: subculture of umbilical cord mesenchymal stem cells
Subculture was performed on the umbilical cord mesenchymal stem cells of the P0 generation obtained in example 2a, as follows:
(b1) inoculating primary (namely P0 generation) mesenchymal stem cells into a T225 bottle according to the density of 5000/cm2, supplementing a passage complete culture medium to 45ml, placing the bottle in a CO2 incubator (5% CO2, 37 ℃, saturation humidity) to culture until the cell fusion degree reaches 70-80% (generally reaching on the 3 rd day), abandoning the old culture medium, cleaning the cells by using a D-hanks solution, adding 5ml of a recombinant pancreatin solution into each bottle for digesting the cells for 2min to ensure that the cells fall off, adding 15ml of the D-hanks solution into each bottle for diluting, combining all cell suspensions into a 50ml centrifugal tube, centrifuging, precipitating the cells by using the passage complete culture medium to obtain the P1 generation mesenchymal stem cells, and then sampling to perform cell counting and activity rate measurement;
(b2) inoculating the mesenchymal stem cells of the P1 generation into a T225 bottle according to the density of 5000/cm2, supplementing a complete subculture medium to 45ml, putting the bottle in a CO2 incubator (5% CO2, 37 ℃, and saturation humidity), and carrying out subculture according to a P1 subculture method to obtain the mesenchymal stem cells of the P2 generation; then, the cells are continuously passaged to the P10 generation by the method of the above P1 generation and P2 generation, and mesenchymal stem cells of each generation are obtained.
Example 23: subculture of umbilical cord mesenchymal stem cells
Subculture was performed on the umbilical cord mesenchymal stem cells of the P0 generation obtained in example 3a, as follows:
(b1) inoculating primary (namely P0 generation) mesenchymal stem cells into a T225 bottle according to the density of 5000/cm2, supplementing a passage complete culture medium to 45ml, placing the bottle in a CO2 incubator (5% CO2, 37 ℃, saturation humidity) to culture until the cell fusion degree reaches 70-80% (generally reaching on the 3 rd day), abandoning the old culture medium, cleaning the cells by using a D-hanks solution, adding 5ml of a recombinant pancreatin solution into each bottle for digesting the cells for 2min to ensure that the cells fall off, adding 15ml of the D-hanks solution into each bottle for diluting, combining all cell suspensions into a 50ml centrifugal tube, centrifuging, precipitating the cells by using the passage complete culture medium to obtain the P1 generation mesenchymal stem cells, and then sampling to perform cell counting and activity rate measurement;
(b2) inoculating the mesenchymal stem cells of the P1 generation into a T225 bottle according to the density of 5000/cm2, supplementing a complete subculture medium to 45ml, putting the bottle in a CO2 incubator (5% CO2, 37 ℃, and saturation humidity), and carrying out subculture according to a P1 subculture method to obtain the mesenchymal stem cells of the P2 generation; then, the cells are continuously passaged to the P10 generation by the method of the above P1 generation and P2 generation, and mesenchymal stem cells of each generation are obtained.
Example 24: subculture of umbilical cord mesenchymal stem cells
Subculture was performed with the umbilical cord mesenchymal stem cells P0 generation obtained in example 4a, as follows:
(b1) inoculating primary (namely P0 generation) mesenchymal stem cells into a T225 bottle according to the density of 5000/cm2, supplementing a passage complete culture medium to 45ml, placing the bottle in a CO2 incubator (5% CO2, 37 ℃, saturation humidity) to culture until the cell fusion degree reaches 70-80% (generally reaching on the 3 rd day), abandoning the old culture medium, cleaning the cells by using a D-hanks solution, adding 5ml of a recombinant pancreatin solution into each bottle for digesting the cells for 2min to ensure that the cells fall off, adding 15ml of the D-hanks solution into each bottle for diluting, combining all cell suspensions into a 50ml centrifugal tube, centrifuging, precipitating the cells by using the passage complete culture medium to obtain the P1 generation mesenchymal stem cells, and then sampling to perform cell counting and activity rate measurement;
(b2) inoculating the mesenchymal stem cells of the P1 generation into a T225 bottle according to the density of 5000/cm2, supplementing a complete subculture medium to 45ml, putting the bottle in a CO2 incubator (5% CO2, 37 ℃, and saturation humidity), and carrying out subculture according to a P1 subculture method to obtain the mesenchymal stem cells of the P2 generation; then, the cells are continuously passaged to the P10 generation by the method of the above P1 generation and P2 generation, and mesenchymal stem cells of each generation are obtained.
Example 25: subculture of umbilical cord mesenchymal stem cells
Subculture was performed on the umbilical cord mesenchymal stem cells of the P0 generation obtained in example 5a, as follows:
(b1) inoculating primary (namely P0 generation) mesenchymal stem cells into a T225 bottle according to the density of 5000/cm2, supplementing a passage complete culture medium to 45ml, placing the bottle in a CO2 incubator (5% CO2, 37 ℃, saturation humidity) to culture until the cell fusion degree reaches 70-80% (generally reaching on the 3 rd day), abandoning the old culture medium, cleaning the cells by using a D-hanks solution, adding 5ml of a recombinant pancreatin solution into each bottle for digesting the cells for 2min to ensure that the cells fall off, adding 15ml of the D-hanks solution into each bottle for diluting, combining all cell suspensions into a 50ml centrifugal tube, centrifuging, precipitating the cells by using the passage complete culture medium to obtain the P1 generation mesenchymal stem cells, and then sampling to perform cell counting and activity rate measurement;
(b2) inoculating the mesenchymal stem cells of the P1 generation into a T225 bottle according to the density of 5000/cm2, supplementing a complete subculture medium to 45ml, putting the bottle in a CO2 incubator (5% CO2, 37 ℃, and saturation humidity), and carrying out subculture according to a P1 subculture method to obtain the mesenchymal stem cells of the P2 generation; then, the cells are continuously passaged to the P10 generation by the method of the above P1 generation and P2 generation, and mesenchymal stem cells of each generation are obtained.
Example 26: subculture of umbilical cord mesenchymal stem cells
Subculture was performed on the umbilical cord mesenchymal stem cells of the P0 generation obtained in example 6a, as follows:
(b1) inoculating primary (namely P0 generation) mesenchymal stem cells into a T225 bottle according to the density of 5000/cm2, supplementing a passage complete culture medium to 45ml, placing the bottle in a CO2 incubator (5% CO2, 37 ℃, saturation humidity) to culture until the cell fusion degree reaches 70-80% (generally reaching on the 3 rd day), abandoning the old culture medium, cleaning the cells by using a D-hanks solution, adding 5ml of a recombinant pancreatin solution into each bottle for digesting the cells for 2min to ensure that the cells fall off, adding 15ml of the D-hanks solution into each bottle for diluting, combining all cell suspensions into a 50ml centrifugal tube, centrifuging, precipitating the cells by using the passage complete culture medium to obtain the P1 generation mesenchymal stem cells, and then sampling to perform cell counting and activity rate measurement;
(b2) inoculating the mesenchymal stem cells of the P1 generation into a T225 bottle according to the density of 5000/cm2, supplementing a complete subculture medium to 45ml, putting the bottle in a CO2 incubator (5% CO2, 37 ℃, and saturation humidity), and carrying out subculture according to a P1 subculture method to obtain the mesenchymal stem cells of the P2 generation; then, the cells are continuously passaged to the P10 generation by the method of the above P1 generation and P2 generation, and mesenchymal stem cells of each generation are obtained.
Example 27: subculture of umbilical cord mesenchymal stem cells
Subculture was performed on the umbilical cord mesenchymal stem cells of the P0 generation obtained in example 7a, as follows:
(b1) inoculating primary (namely P0 generation) mesenchymal stem cells into a T225 bottle according to the density of 5000/cm2, supplementing a passage complete culture medium to 45ml, placing the bottle in a CO2 incubator (5% CO2, 37 ℃, saturation humidity) to culture until the cell fusion degree reaches 70-80% (generally reaching on the 3 rd day), abandoning the old culture medium, cleaning the cells by using a D-hanks solution, adding 5ml of a recombinant pancreatin solution into each bottle for digesting the cells for 2min to ensure that the cells fall off, adding 15ml of the D-hanks solution into each bottle for diluting, combining all cell suspensions into a 50ml centrifugal tube, centrifuging, precipitating the cells by using the passage complete culture medium to obtain the P1 generation mesenchymal stem cells, and then sampling to perform cell counting and activity rate measurement;
(b2) inoculating the mesenchymal stem cells of the P1 generation into a T225 bottle according to the density of 5000/cm2, supplementing a complete subculture medium to 45ml, putting the bottle in a CO2 incubator (5% CO2, 37 ℃, and saturation humidity), and carrying out subculture according to a P1 subculture method to obtain the mesenchymal stem cells of the P2 generation; then, the cells are continuously passaged to the P10 generation by the method of the above P1 generation and P2 generation, and mesenchymal stem cells of each generation are obtained.
Example 28: subculture of umbilical cord mesenchymal stem cells
Subculture was performed on the umbilical cord mesenchymal stem cells of the P0 generation obtained in example 8a, as follows:
(b1) inoculating primary (namely P0 generation) mesenchymal stem cells into a T225 bottle according to the density of 5000/cm2, supplementing a passage complete culture medium to 45ml, placing the bottle in a CO2 incubator (5% CO2, 37 ℃, saturation humidity) to culture until the cell fusion degree reaches 70-80% (generally reaching on the 3 rd day), abandoning the old culture medium, cleaning the cells by using a D-hanks solution, adding 5ml of a recombinant pancreatin solution into each bottle for digesting the cells for 2min to ensure that the cells fall off, adding 15ml of the D-hanks solution into each bottle for diluting, combining all cell suspensions into a 50ml centrifugal tube, centrifuging, precipitating the cells by using the passage complete culture medium to obtain the P1 generation mesenchymal stem cells, and then sampling to perform cell counting and activity rate measurement;
(b2) inoculating the mesenchymal stem cells of the P1 generation into a T225 bottle according to the density of 5000/cm2, supplementing a complete subculture medium to 45ml, putting the bottle in a CO2 incubator (5% CO2, 37 ℃, and saturation humidity), and carrying out subculture according to a P1 subculture method to obtain the mesenchymal stem cells of the P2 generation; then, the cells are continuously passaged to the P10 generation by the method of the above P1 generation and P2 generation, and mesenchymal stem cells of each generation are obtained.
The cell viability rates of the P1-P10 generation cells obtained in examples 21-28 were measured by trypan blue staining method, and as a result, the cell viability rates of the P1-P10 generation cells obtained in example 21 were all in the range of 90-96%, the cell viability rates of the P1-P10 generation cells obtained in example 22 were all in the range of 91-95%, the cell viability rates of the P1-P10 generation cells obtained in example 23 were all in the range of 89-94%, the cell viability rates of the P1-P10 generation cells obtained in example 24 were all in the range of 89-95%, the cell viability rates of the P1-P10 generation cells obtained in example 25 were all in the range of 88-97%, the cell viability rates of the P1-P10 generation cells obtained in example 26 were all in the range of 90-96%, the cell viability rates of the P1-P10 generation cells obtained in example 27 were all in the range of 90-90%, and the cell viability rates of the P1-P10 generation cells obtained in the example 27 were in the range of the P6328-366-3594%, and the cell viability rates of the P1-3693% 96.7%, 95.1%, 90.3%, 92.4%, 90.8%, 91.3%, 94.1%, 93.4%, 93.3%.
Example 31: subculture of adipose tissue-derived stem cells
Subculturing of adipose-derived mesenchymal stem cells was performed with reference to example 21, except that the amount of thioglycerol added to the used complete subculture medium was 0.1%, to obtain adipose-derived mesenchymal stem cells of P1-P10 generations, which were examined for cell viability by trypan blue staining, and as a result, the cell viability of the cells of P1-P6 generations were all in the range of 81-94% and decreased with the passage increment, for example, the cell viability of the P1 generation and the P6 generation were 93.4% and 81.3%, respectively; the cell survival rates of the cells from the P7 generations to the P10 generations are continuously reduced and are all in the range of 59-78%, and the cell survival rates are reduced along with the increment of the generations, for example, the cell survival rates of the P7 generations and the P10 generations are 77.4% and 59.3%, respectively. The results of this example show that the effect of adding higher amounts of thioglycerol to the passaged complete medium on cell viability is detrimental.
Example 32: subculture of umbilical cord mesenchymal stem cells
The subculture of umbilical cord mesenchymal stem cells was carried out with reference to example 21, except that thioglycerol was not added to the used subculture complete medium, to obtain umbilical cord mesenchymal stem cells of generations P1-P10, and the cells were examined for viability by trypan blue staining, with the results that the viability of the cells of generations P1-P10 was in the range of 63-92% and decreased with increasing passage, for example, the viability of the cells of generations P2 and P8 was 88.6% and 67.4%, respectively. The results of this example show that the effect of not adding thioglycerol to the passaged complete medium on cell viability is adverse.
Example 33: subculture of umbilical cord mesenchymal stem cells
The subculture of umbilical cord mesenchymal stem cells was carried out with reference to example 21, except that fructose was not added to the used subculture complete medium, to obtain umbilical cord mesenchymal stem cells of generations P1-P10, and the viability of the cells was examined by trypan blue staining method, and as a result, the viability of the cells of generations P1-P10 was in the range of 67-94% and decreased with the passage increment, for example, the viability of the cells of generations P2 and P8 was 90.4% and 74.4%, respectively. The results of this example show that the effect of not adding fructose to the passaged complete medium on cell viability is unfavorable.
Test example 1: detection of mesenchymal stem cells
Typical characteristics of mesenchymal stem cells include: microscopic fusiform and adherent growth, flow cytometry identification shows that CD73, CD90 and CD105 are all positive and CD19, CD11b, CD31, CD45, HLADR and CD34 are all negative, and a directional differentiation potential test shows that the cells present the differentiation potential of osteogenesis, chondrogenesis and adipogenesis.
The mesenchymal stem cells prepared in the embodiments 1 to 12 and the auxiliary a, b and c examples thereof are detected by using a method known in the field, and the results are as follows: all mesenchymal stem cells exhibited spindle and adherent growth (e.g., microscopic cell morphology of the mesenchymal stem cells of generation P0 obtained in example 1a is shown in fig. 1), CD73, CD90 and CD105 of all mesenchymal stem cells were greater than 98% (e.g., CD73 ═ 99.1%, CD90 ═ 98.7%, CD105 ═ 99.6% of a batch of the mesenchymal stem cells of generation P0 obtained in example 1 a), CD19, CD11b, CD31, CD45 of all mesenchymal stem cells, HLADR and CD34 are less than 2% (e.g., CD19 of the batch of the P0-generation mesenchymal stem cells obtained in example 1a is 0.11%, CD11b is 0.23%, CD31 is 0.07%, CD45 is 0.12%, HLADR is 0.08%, and CD34 is 0.14%), and the directed differentiation potential test shows that all the mesenchymal stem cells have osteogenic, chondrogenic and adipogenic differentiation potential (e.g., the differentiation potential results of the batch of the P0-generation mesenchymal stem cells obtained in example 1a are shown in fig. 2).
In addition, 8P 10 generation cells obtained in examples 21 to 28 of the present invention were examined by methods known in the art, and the results were as follows: all mesenchymal stem cells exhibited fusiform and adherent growth, CD73, CD90 and CD105 of 8 cells were greater than 98% (e.g., CD73 ═ 99.1%, CD90 ═ 98.7%, CD105 ═ 99.4% for the P10-generation mesenchymal stem cells of example 21), CD19, CD11b, CD31, CD45, HLADR, CD34 of 8 cells were less than 2% (e.g., CD19 ═ 0.36%, CD11b ═ 0.42%, CD31 ═ 0.18%, CD45 ═ 0.14%, HLADR ═ 0.46%, CD34 ═ 0.35% for the P10-generation mesenchymal stem cells of example 21), and directed differentiation experiments showed that all mesenchymal stem cells had osteogenic, adipogenic, chondrogenic differentiation potential (not shown).
The above-described embodiments are merely preferred embodiments for fully illustrating the present application, and the scope of the present application is not limited thereto. The equivalent substitution or change made by the person skilled in the art on the basis of the present application is within the protection scope of the present application. The protection scope of this application is subject to the claims.
Claims (10)
1. The method for subculturing the umbilical cord mesenchymal stem cells comprises the following steps:
(b1) inoculating primary (namely P0 generation) mesenchymal stem cells into a T225 bottle according to the density of 5000/cm2, supplementing a passage complete culture medium to 45ml, placing the bottle in a CO2 incubator (5% CO2, 37 ℃, saturation humidity) to culture until the cell fusion degree reaches 70-80% (generally reaching on the 3 rd day), abandoning the old culture medium, cleaning the cells by using a D-hanks solution, adding 5ml of a recombinant pancreatin solution into each bottle for digesting the cells for 2min to ensure that the cells fall off, adding 15ml of the D-hanks solution into each bottle for diluting, combining all cell suspensions into a 50ml centrifugal tube, centrifuging, precipitating the cells by using the passage complete culture medium to obtain the P1 generation mesenchymal stem cells, and then sampling to perform cell counting and activity rate measurement;
(b2) inoculating the mesenchymal stem cells of the P1 generation into a T225 bottle according to the density of 5000/cm2, supplementing a complete subculture medium to 45ml, putting the bottle in a CO2 incubator (5% CO2, 37 ℃, and saturation humidity), and carrying out subculture according to a P1 subculture method to obtain the mesenchymal stem cells of the P2 generation; then, the cells are continuously passaged to the P10 generation by the method of the above P1 generation and P2 generation, and mesenchymal stem cells of each generation are obtained.
2. The method according to claim 1, wherein
The formula of the D-Hanks liquid comprises the following components: 8.0g NaCl, 0.4g KCl, 0.06g KH2PO4, 0.08g Na2HPO4.12H2O, 0.35g NaHCO3 and water to 1000 ml; for example, the preparation method is as follows: dissolving the materials in 1000ml, and filtering with 0.22 μm microporous membrane for sterilization;
the complete subculture medium is prepared by taking a DMEM-F12 medium as a matrix and comprises the following components: 2% platelet lysate, 1% human serum albumin, 2 μ g/ml recombinant insulin, 10ng/ml EGF, 15ng/ml bFGF, 0.035% thioglycerol, 1% fructose; and/or
The DMEM-F12 medium formula comprises the following components: 116.6mg of anhydrous calcium chloride, 59.05mg of L-leucine, 0.042mg of linoleic acid, 0.0013mg of copper sulfate pentahydrate, 91.25mg of L-lysine hydrochloride, 0.105mg of lipoic acid, 0.05mg of ferric nitrate nonahydrate, 17.24mg of L-methionine, 8.1mg of phenol red, 0.417mg of ferrous sulfate heptahydrate, 35.48mg of L-phenylalanine, 0.081mg of 1, 4-butanediamine dihydrochloride, 311.8mg of potassium chloride, 26.25mg of L-serine, 55mg of sodium pyruvate, 28.64mg of magnesium chloride, 53.45mg of L-threonine, 0.0035mg of vitamin H, 48.84mg of anhydrous magnesium sulfate, 4.45mg of L-alanine, 2.24mg of D-calcium pantothenate, 7000mg of sodium chloride, 7.5mg of L-asparagine, 8.98mg of choline chloride, 54.35mg of anhydrous sodium dihydrogen phosphate, 6.65mg of L-aspartic acid, 2.65mg of L-cysteine, 56.52 mg of L-disodium hydrogen phosphate, 17.12 mg of L-17 mg of inositol phosphate, 6.52 mg of L-asparagine, 0.432mg of zinc sulfate heptahydrate, 7.35mg of L-glutamic acid, 2.02mg of nicotinamide, 147.5mg of L-arginine hydrochloride, 17.25mg of L-proline, 2mg of pyridoxal hydrochloride, 31.29mg of L-cystine hydrochloride, 9.02mg of L-tryptophan, 0.031mg of pyridoxine hydrochloride, 365mg of L-glutamine, 38.4mg of L-tyrosine, 0.219mg of riboflavin, 18.75mg of glycine, 52.85mg of L-valine, 2.17mg of thiamine hydrochloride, 31.48mg of L-histidine hydrochloride, 3151mg of D-glucose, 0.365mg of thymidine, 54.47mg of L-isoleucine, 2mg of hypoxanthine, 0.68mg of vitamin B12 and adding a proper amount of water to 1000 mL; preparation: dissolving the materials in 1000ml, and filtering with 0.22 μm microporous membrane for sterilization.
3. A method for isolating and subculturing umbilical cord mesenchymal stem cells, comprising two stages of (a) isolating and culturing primary umbilical cord mesenchymal stem cells and (b) subculturing umbilical cord mesenchymal stem cells, wherein
(a) The stage of separating and culturing the primary umbilical cord mesenchymal stem cells comprises the following steps:
(a1) treating the umbilical cord sample transported to a laboratory through a cold chain at 2-8 ℃ in a biosafety cabinet;
(a2) D-Hanks is fully cleaned to remove surface bloodiness, the umbilical cord is cut into small sections by using a surgical scissors, the small sections are placed in a plate, the small sections are repeatedly squeezed by using surgical forceps, residual blood clots in tissues are removed, and the umbilical cord is cleaned by using the D-Hanks;
(a3) cutting tissue, peeling off epidermis, removing artery and vein to obtain tissue of Wharton jelly, cutting Wharton jelly into small pieces, and weighing;
(a4) inoculating the tissue to a culture bottle according to a specified tissue quantity, adding a primary complete culture medium, fully and uniformly mixing to enable tissue blocks to be uniformly spread on the bottom of the bottle, and culturing in a CO2 culture box;
(a5) culturing until the 3 rd supplemented complete culture medium is continuously cultured, continuing culturing until the 5 th supplemented primary complete culture medium is continuously cultured, completely replacing the culture solution until the 7 th cell fusion degree reaches more than 80%, removing the old culture medium, cleaning the cells by using D-hanks liquid, adding recombinant pancreatin solution to digest the cells to make the cells fall off, adding the D-hanks liquid to dilute, centrifuging, and re-suspending the cell precipitate by using the primary complete culture medium to obtain primary umbilical cord mesenchymal stem cells (namely P0 generation);
(b) the stage of subculturing the umbilical cord mesenchymal stem cells comprises the following steps:
(b1) inoculating primary (namely P0 generation) mesenchymal stem cells into a T225 bottle according to the density of 5000/cm2, supplementing a passage complete culture medium to 45ml, placing the bottle in a CO2 incubator (5% CO2, 37 ℃, saturation humidity) to culture until the cell fusion degree reaches 70-80% (generally reaching on the 3 rd day), abandoning the old culture medium, cleaning the cells by using a D-hanks solution, adding 5ml of a recombinant pancreatin solution into each bottle for digesting the cells for 2min to ensure that the cells fall off, adding 15ml of the D-hanks solution into each bottle for diluting, combining all cell suspensions into a 50ml centrifugal tube, centrifuging, precipitating the cells by using the passage complete culture medium to obtain the P1 generation mesenchymal stem cells, and then sampling to perform cell counting and activity rate measurement;
(b2) inoculating the mesenchymal stem cells of the P1 generation into a T225 bottle according to the density of 5000/cm2, supplementing a complete subculture medium to 45ml, putting the bottle in a CO2 incubator (5% CO2, 37 ℃, and saturation humidity), and carrying out subculture according to a P1 subculture method to obtain the mesenchymal stem cells of the P2 generation; then, the cells are continuously passaged to the P10 generation by the method of the above P1 generation and P2 generation, and mesenchymal stem cells of each generation are obtained.
4. A method according to claim 3, wherein:
in the step (a3), the Walsh gum is cut into 0.25cm2Small pieces of size;
in the step (a4), the step of inoculating the tissue blocks into the culture bottle according to the specified tissue quantity means that 1.5g of the tissue blocks of the Wharton jelly obtained in the step (3) are weighed and inoculated into a T225 culture bottle;
in the step (a4), adding 15ml of primary complete culture medium into each bottle, fully and uniformly mixing, uniformly spreading tissue blocks at the bottom of the bottle, and culturing in a CO2 incubator;
in step (a4), CO2The conditions for the culture in the incubator were: 5% CO2Saturated humidity at 37 ℃;
in the step (a5), the culture is continued until the 3 rd supplement of 10ml of primary complete culture medium;
in the step (a5), the culture is continued until the 5d is supplemented with 10ml of primary complete culture medium;
in the step (a5), 5ml of recombinant pancreatin solution is added into each bottle to digest cells for 2 min;
in the step (a5), adding 25ml of D-hanks liquid into each bottle for dilution; and/or
In step (a5), centrifugation was carried out at 100Xg for 10 min.
5. A method according to claim 3, wherein:
the formula of the D-Hanks liquid comprises the following components: 8.0g NaCl, 0.4g KCl, 0.06g KH2PO4, 0.08g Na2HPO4.12H2O, 0.35g NaHCO3 and water to 1000 ml; for example, the preparation method is as follows: dissolving the materials in 1000ml, and filtering with 0.22 μm microporous membrane for sterilization;
the primary complete culture medium is prepared by taking a DMEM-F12 culture medium as a matrix and comprises the following components: 0.8% platelet lysate, 1% human serum albumin, 2 μ g/ml recombinant insulin, 15ng/ml EGF, 25ng/ml bFGF;
replacing the primary complete culture medium with a primary supplementary culture medium;
the primary supplementary culture medium is prepared by taking DMEM-F12 medium as a matrix and comprises the following components: 0.8% platelet lysate, 1% human serum albumin, 2 μ g/ml recombinant insulin, 15ng/ml EGF, 25ng/ml bFGF, 0.1% thioglycerol, 1% fructose; and/or
The DMEM-F12 medium formula comprises the following components: 116.6mg of anhydrous calcium chloride, 59.05mg of L-leucine, 0.042mg of linoleic acid, 0.0013mg of copper sulfate pentahydrate, 91.25mg of L-lysine hydrochloride, 0.105mg of lipoic acid, 0.05mg of ferric nitrate nonahydrate, 17.24mg of L-methionine, 8.1mg of phenol red, 0.417mg of ferrous sulfate heptahydrate, 35.48mg of L-phenylalanine, 0.081mg of 1, 4-butanediamine dihydrochloride, 311.8mg of potassium chloride, 26.25mg of L-serine, 55mg of sodium pyruvate, 28.64mg of magnesium chloride, 53.45mg of L-threonine, 0.0035mg of vitamin H, 48.84mg of anhydrous magnesium sulfate, 4.45mg of L-alanine, 2.24mg of D-calcium pantothenate, 7000mg of sodium chloride, 7.5mg of L-asparagine, 8.98mg of choline chloride, 54.35mg of anhydrous sodium dihydrogen phosphate, 6.65mg of L-aspartic acid, 2.65mg of L-cysteine, 56.52 mg of L-disodium hydrogen phosphate, 17.12 mg of L-17 mg of inositol phosphate, 6.52 mg of L-asparagine, 0.432mg of zinc sulfate heptahydrate, 7.35mg of L-glutamic acid, 2.02mg of nicotinamide, 147.5mg of L-arginine hydrochloride, 17.25mg of L-proline, 2mg of pyridoxal hydrochloride, 31.29mg of L-cystine hydrochloride, 9.02mg of L-tryptophan, 0.031mg of pyridoxine hydrochloride, 365mg of L-glutamine, 38.4mg of L-tyrosine, 0.219mg of riboflavin, 18.75mg of glycine, 52.85mg of L-valine, 2.17mg of thiamine hydrochloride, 31.48mg of L-histidine hydrochloride, 3151mg of D-glucose, 0.365mg of thymidine, 54.47mg of L-isoleucine, 2mg of hypoxanthine, 0.68mg of vitamin B12 and adding a proper amount of water to 1000 mL; for example, the preparation method is as follows: dissolving the materials in 1000ml, and filtering with 0.22 μm microporous membrane for sterilization.
6. The method according to claim 3, further comprising detecting the primary umbilical cord mesenchymal stem cells obtained from the isolated culture. For example, detection of cellular morphology and/or immunophenotypic identification; for example, the immunophenotypic identification refers to detection of CD73, CD90, CD105 and CD19, CD11b, CD31, CD45, HLADR, CD 34; for example, the obtained primary umbilical cord mesenchymal stem cells are positive for CD73, CD90 and CD105 (all greater than 98%), and negative for CD19, CD11b, CD31, CD45, HLADR and CD34 (all less than 2%).
7. The method according to claim 3, wherein said subculture completion medium is prepared from DMEM-F12 medium and comprises: 2% platelet lysate, 1% human serum albumin, 2. mu.g/ml recombinant insulin, 10ng/ml EGF, 15ng/ml bFGF, 0.035% thioglycerol, 1% fructose.
8. A complete passage culture medium for passage culture of umbilical cord mesenchymal stem cells is prepared by taking a DMEM-F12 culture medium as a matrix and comprises: 2% platelet lysate, 1% human serum albumin, 2. mu.g/ml recombinant insulin, 10ng/ml EGF, 15ng/ml bFGF, 0.035% thioglycerol, 1% fructose.
9. Use of a serum-free medium, also referred to as passage complete medium, formulated with DMEM-F12 medium as a matrix and comprising: 2% platelet lysate, 1% human serum albumin, 2. mu.g/ml recombinant insulin, 10ng/ml EGF, 15ng/ml bFGF, 0.035% thioglycerol, 1% fructose.
10. The passaged complete medium of claim 8 or the use of claim 9 wherein the DMEM-F12 medium formula consists of: 116.6mg of anhydrous calcium chloride, 59.05mg of L-leucine, 0.042mg of linoleic acid, 0.0013mg of copper sulfate pentahydrate, 91.25mg of L-lysine hydrochloride, 0.105mg of lipoic acid, 0.05mg of ferric nitrate nonahydrate, 17.24mg of L-methionine, 8.1mg of phenol red, 0.417mg of ferrous sulfate heptahydrate, 35.48mg of L-phenylalanine, 0.081mg of 1, 4-butanediamine dihydrochloride, 311.8mg of potassium chloride, 26.25mg of L-serine, 55mg of sodium pyruvate, 28.64mg of magnesium chloride, 53.45mg of L-threonine, 0.0035mg of vitamin H, 48.84mg of anhydrous magnesium sulfate, 4.45mg of L-alanine, 2.24mg of D-calcium pantothenate, 7000mg of sodium chloride, 7.5mg of L-asparagine, 8.98mg of choline chloride, 54.35mg of anhydrous sodium dihydrogen phosphate, 6.65mg of L-aspartic acid, 2.65mg of L-cysteine, 56.52 mg of L-disodium hydrogen phosphate, 17.12 mg of L-17 mg of inositol phosphate, 6.52 mg of L-asparagine, 0.432mg of zinc sulfate heptahydrate, 7.35mg of L-glutamic acid, 2.02mg of nicotinamide, 147.5mg of L-arginine hydrochloride, 17.25mg of L-proline, 2mg of pyridoxal hydrochloride, 31.29mg of L-cystine hydrochloride, 9.02mg of L-tryptophan, 0.031mg of pyridoxine hydrochloride, 365mg of L-glutamine, 38.4mg of L-tyrosine, 0.219mg of riboflavin, 18.75mg of glycine, 52.85mg of L-valine, 2.17mg of thiamine hydrochloride, 31.48mg of L-histidine hydrochloride, 3151mg of D-glucose, 0.365mg of thymidine, 54.47mg of L-isoleucine, 2mg of hypoxanthine, 0.68mg of vitamin B12 and adding a proper amount of water to 1000 mL; for example, the preparation method is as follows: dissolving the materials in 1000ml, and filtering with 0.22 μm microporous membrane for sterilization.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011567586.1A CN112608892B (en) | 2020-12-25 | 2020-12-25 | Method for serum-free separation and subculturing of umbilical cord mesenchymal stem cells by using platelet lysate |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011567586.1A CN112608892B (en) | 2020-12-25 | 2020-12-25 | Method for serum-free separation and subculturing of umbilical cord mesenchymal stem cells by using platelet lysate |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN112608892A true CN112608892A (en) | 2021-04-06 |
| CN112608892B CN112608892B (en) | 2023-11-14 |
Family
ID=75248187
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011567586.1A Active CN112608892B (en) | 2020-12-25 | 2020-12-25 | Method for serum-free separation and subculturing of umbilical cord mesenchymal stem cells by using platelet lysate |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112608892B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113234662A (en) * | 2021-05-08 | 2021-08-10 | 康妍葆(北京)干细胞科技有限公司 | Stem cell serum-free culture medium and preparation method and application thereof |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090238801A1 (en) * | 2006-06-28 | 2009-09-24 | University Of Medicine And Dentistry Of New Jersey | Amnion-derived stem cells and uses thereof |
| WO2014093598A1 (en) * | 2012-12-14 | 2014-06-19 | DePuy Synthes Products, LLC | NUTRIENT ENRICHED MEDIA FOR hUTC GROWTH |
| CN104640974A (en) * | 2012-07-24 | 2015-05-20 | 日产化学工业株式会社 | Culture medium composition, and method for culturing cell or tissue using said composition |
| CN104774808A (en) * | 2015-03-27 | 2015-07-15 | 安沂华 | Method for inducible differentiation of umbilical cord mesenchymal stem cells into gamma-aminobutyric acid-ergic neuron |
| WO2017096611A1 (en) * | 2015-12-11 | 2017-06-15 | 郭镭 | Method for separating and culturing mesenchymal stem cells from wharton's jelly tissue of umbilical cord |
| CN108004207A (en) * | 2017-12-15 | 2018-05-08 | 英科博雅生命科技有限公司 | The method that significant quantities of fat mescenchymal stem cell is obtained from fat |
| TW201900213A (en) * | 2017-05-27 | 2019-01-01 | 美商免疫醫療公司 | Modulation of immunoglobulin-A-positive cells |
| WO2020012991A1 (en) * | 2018-07-09 | 2020-01-16 | ロート製薬株式会社 | Mesenchymal stem cell and therapeutic agent for neuropathy |
-
2020
- 2020-12-25 CN CN202011567586.1A patent/CN112608892B/en active Active
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090238801A1 (en) * | 2006-06-28 | 2009-09-24 | University Of Medicine And Dentistry Of New Jersey | Amnion-derived stem cells and uses thereof |
| CN104640974A (en) * | 2012-07-24 | 2015-05-20 | 日产化学工业株式会社 | Culture medium composition, and method for culturing cell or tissue using said composition |
| WO2014093598A1 (en) * | 2012-12-14 | 2014-06-19 | DePuy Synthes Products, LLC | NUTRIENT ENRICHED MEDIA FOR hUTC GROWTH |
| CN104774808A (en) * | 2015-03-27 | 2015-07-15 | 安沂华 | Method for inducible differentiation of umbilical cord mesenchymal stem cells into gamma-aminobutyric acid-ergic neuron |
| WO2017096611A1 (en) * | 2015-12-11 | 2017-06-15 | 郭镭 | Method for separating and culturing mesenchymal stem cells from wharton's jelly tissue of umbilical cord |
| TW201900213A (en) * | 2017-05-27 | 2019-01-01 | 美商免疫醫療公司 | Modulation of immunoglobulin-A-positive cells |
| CN108004207A (en) * | 2017-12-15 | 2018-05-08 | 英科博雅生命科技有限公司 | The method that significant quantities of fat mescenchymal stem cell is obtained from fat |
| WO2020012991A1 (en) * | 2018-07-09 | 2020-01-16 | ロート製薬株式会社 | Mesenchymal stem cell and therapeutic agent for neuropathy |
Non-Patent Citations (1)
| Title |
|---|
| 施 沁等: ""人脐带华通氏胶间充质干细胞定向分化：现状与前景"", 《中国组织工程研究》, vol. 22, no. 5, pages 793 - 800 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113234662A (en) * | 2021-05-08 | 2021-08-10 | 康妍葆(北京)干细胞科技有限公司 | Stem cell serum-free culture medium and preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN112608892B (en) | 2023-11-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103583511B (en) | A kind of mesenchymal stem cell cryopreserving liquid and parenteral solution | |
| US8871513B2 (en) | Culture medium composition for culturing amnion-derived mesenchymal stem cell, and method for culturing amnion-derived mesenchymal stem cell by using same | |
| CN110923196B (en) | Serum-free medium, preparation method thereof and mesenchymal stem cell culture method | |
| CN112481202B (en) | Method for serum-free separation culture of umbilical cord mesenchymal stem cells by using platelet lysate | |
| EP2865749A1 (en) | High-concentration stem cell production method | |
| CN108004207B (en) | Method for obtaining large amount of adipose mesenchymal stem cells from fat | |
| WO2005035738A1 (en) | Cell differentiation of adipose-derived precursor cells | |
| CN109234229B (en) | Method for separating mesenchymal stem cells from placental blood vessels and digestive enzyme composition used in same | |
| EP3385372B1 (en) | Method for manufacturing mesenchymal cell line derived from vertebrate animal adipose tissue | |
| CN110938590B (en) | Mesenchymal stem cell serum-free medium and application thereof | |
| CN107858329B (en) | Method for separating adipose-derived mesenchymal stem cells from fat and test solution used in method | |
| CN112111448B (en) | Improved mesenchymal stem cell culture medium, bone marrow mesenchymal stem cell, and culture method and application thereof | |
| CN107083359B (en) | Stem cell culture medium and stem cell separation method | |
| CN112300986B (en) | Method for preparing adipose-derived mesenchymal stem cells by serum-free medium | |
| CN109628388B (en) | Isolation of mesenchymal stem cells from placental blood vessels with digestive enzyme composition | |
| KR20160079390A (en) | Composition of Media for Culturing Stem Cell | |
| CN112608892B (en) | Method for serum-free separation and subculturing of umbilical cord mesenchymal stem cells by using platelet lysate | |
| KR101753557B1 (en) | Culture medium composition for promoting stem cell proliferation and methods for culturing stem cell | |
| CN112458047B (en) | Method for separating placenta mesenchymal stem cells and serum-free culture medium used by same | |
| EP3381458B1 (en) | Therapeutic agent for liver disease containing stromal cells derived from adipose tissue and method for producing the same | |
| CN112522193B (en) | Application of serum-free culture medium in separation and passage of adipose-derived mesenchymal stem cells | |
| CN117305236A (en) | Adipose-derived mesenchymal stem cell low-oxygen atmosphere culture and application thereof in treating premature ovarian failure | |
| CN112608893B (en) | Separation and purification method of placenta mesenchymal stem cells | |
| CN114752560B (en) | Umbilical cord mesenchymal stem cell culture medium | |
| CN113215095B (en) | Compositions, media supplements, and stem cell media and methods of culture |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |